[go: nahoru, domu]

Jump to content

User talk:Peter morrell/Selection of studies: Difference between revisions

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia
Content deleted Content added
I suggest you look at Help:Table and wikify the table code like I did with the header and first row. (I didn't include any font tags or cell size tags, so it's a bit uglier, u can beautify later)
updated version, apparently. Copied from my talk page
Line 1: Line 1:
Dear Tim,<br>
Dear Tim,<br>
Please put this on the Talk:Homeopathy Page and mention it is posted by me (or else the others may think I've bribed you); I'm not yet able to post there directly myself because the Page is semi-writeprotected.<br>
Please put this on the Talk:Homeopathy Page and mention it is posted by me (or else the others may think I've bribed you); I'm not yet able to post there directly myself because the Page is semi-writeprotected.<br>
Here are some of the studies/clinical trials:-</p>
<p>Here are some of the studies/clinical trials:-</p>
<p><b>STUDIES OF THE ACTIVITY OF HOMEOPATHIC MEDICINES</b></p>
<b>
<table border="1" cellpadding="0" style="mso-cellspacing: 1.5pt; mso-table-layout-alt: fixed" height="1087">
<p align="left">STUDIES OF THE ACTIVITY OF HOMEOPATHIC MEDICINES</p>
<div align="left">
<tr style="height:6.75pt">
<table height="172" width="678" border="1">
<td width="162" style="width: 121.6pt; padding: .75pt" height="21">
<p class="MsoNormal" style="mso-line-height-alt:6.75pt"><span style="font-size:
<tr>
<td width="171" height="9"><font size="1">ORIGINAL/TRANSLATED TITLE</font></td>
7.5pt">ORIGINAL/TRANSLATED TITLE</span></p>
</td>
<td width="128" height="9">AUTHOR(S)</td>
<td width="84" height="9">PUBLICATION</td>
<td width="121" style="width: 91.05pt; padding: .75pt" height="21">
<td width="92" height="9">ACTIVITY</td>
<p class="MsoNormal" style="mso-line-height-alt:6.75pt">AUTHOR(S)</p>
</td>
<td width="203" height="9">STUDY</td>
<td width="111" style="width: 83.0pt; padding: .75pt" height="21">
</tr>
<p class="MsoNormal" style="mso-line-height-alt:6.75pt">PUBLICATION</p>
<tr>
</td>
<td width="171" height="9"><font face="Optima-Bold" size="1"><b>
<td width="90" style="width: 67.45pt; padding: .75pt" height="21">
<p align="left">Inhibition of lymphoblast</b></font></b> <font face="Optima-Bold" size="1"><b>transformation
<p class="MsoNormal" style="mso-line-height-alt:6.75pt">ACTIVITY</p>
test (LTT) in</b></font> <font face="Optima-Bold" size="1"><b>phytohaemagglutinin
</td>
(PHA) with</b></font> <font face="Optima-Bold" size="1"><b>Phytolacca
<td width="84" style="width: 62.9pt; padding: .75pt" height="21">
americana in</b></font> <b><font face="Optima-Bold" size="1">homeopathic
<p class="MsoNormal" style="mso-line-height-alt:6.75pt">STUDY</p>
dilution</font></b></p>
</td>
</td>
</tr>
<td width="128" height="9"><font face="Optima" size="1">
<tr style="height:6.75pt">
<p align="left">Colas H.,</p>
<td width="162" style="width: 121.6pt; padding: .75pt" height="51">
<p align="left">Aubin M.,</p>
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Inhibition of
<p align="left">Picard P.,</p>
<p align="left">Lebecq J.C.</font></p>
lymphoblast</span></b><span style="font-size:7.5pt;font-family:Optima-Bold"><br>
<b>transformation test (LTT) in</b><br>
</td>
<b>phytohaemagglutinin (PHA) with</b><br>
<td width="84" height="9"><i><font face="Optima-Oblique" size="1">
<p align="left">Ann. Homéopat.</p>
<b>Phytolacca americana in</b><br>
<b>homeopathic dilution</b></span></p>
<p align="left">Fr.</font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">1975</font></b><font face="Optima" size="1">,
6: 1-11.</font></p>
</td>
<td width="121" style="width: 91.05pt; padding: .75pt" height="51">
</td>
<p><span style="font-size:7.5pt;font-family:Optima">Colas H.,<br>
<td width="92" height="9"><b>
Aubin M.,<br>
<p align="left"><font face="Optima-Bold" size="1">Inhibitory</font></b></p>
</td>
Picard P.,<br>
<td width="203" height="9">
Lebecq J.C.</span></p>
</td>
<p align="left"><font face="Optima" size="1">Lymphoblast</p>
<td width="111" style="width: 83.0pt; padding: .75pt" height="51">
<p align="left">transformation</font></p>
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Ann. Homéopat.<o:p>
</td>
</tr>
</o:p>
<tr>
</span></i></p>
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Fr.</span></i><span style="font-size:7.5pt;font-family:Optima">,
<td width="171" height="9"><font face="Optima-Bold" size="1"><b>
</span><b><span style="font-size:7.5pt;font-family:Optima-Bold">1975</span></b><span style="font-size:7.5pt;font-family:Optima">,
<p align="left">Inquiry into the limits of biological</b></font> <font face="Optima-Bold" size="1"><b>effects
6: 1-11.</span></p>
of chemical compounds in</b></font> <font face="Optima-Bold" size="1"><b>tissue
</td>
culture. I. Low dose effects of</b></font> <b><font face="Optima-Bold" size="1">mercure
<td width="90" style="width: 67.45pt; padding: .75pt" height="51">
chloride</font></b></p>
<p style="mso-line-height-alt:6.75pt"><b><span style="font-size:7.5pt;
</td>
font-family:Optima-Bold">Inhibitory</span></b></p>
<td width="128" height="9"><font face="Optima" size="1">
</td>
<p align="left">Mansvelt J.D.,</p>
<td width="84" style="width: 62.9pt; padding: .75pt" height="51">
<p align="left">van Amons E.</font></p>
<p><span style="font-size:7.5pt;font-family:Optima">Lymphoblast<o:p>
</td>
<td width="84" height="9">
</o:p>
</span></p>
<p align="left"><i><font face="Optima-Oblique" size="1">Z.
<p style="mso-line-height-alt:6.75pt"><span style="font-size:7.5pt;
Naturtorschung</font></i><font face="Optima" size="1">,</p>
font-family:Optima">transformation</span></p>
</font><b><font face="Optima-Bold" size="1">
</td>
<p align="left">1975</font></b><font face="Optima" size="1">, 30:</p>
</tr>
<p align="left">643-649.</font></p>
<tr style="height:6.75pt">
</td>
<td width="92" height="9"><b>
<td width="162" style="width: 121.6pt; padding: .75pt" height="38">
<p align="left"><font face="Optima-Bold" size="1">Inhibitory</font></b></p>
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Inquiry into
the limits of biological</span></b> <span style="font-size:7.5pt;font-family:
</td>
Optima-Bold"><b>effects of chemical compounds in</b></span> <b><span style="font-size:7.5pt;font-family:Optima-Bold">tissue
<td width="203" height="9"><font face="Optima" size="1">
culture. I. Low dose effects of</span></b> <b><span style="font-size:7.5pt;font-family:Optima-Bold">mercuric
<p align="left">Lymphocyte</p>
<p align="left">growth</font></p>
chloride</span></b></p>
</td>
</td>
<td width="121" style="width: 91.05pt; padding: .75pt" height="38"><span style="font-size: 7.5pt; font-family: Optima">Mansvelt J.D.,<br>
</tr>
van Amons E.</span></td>
<tr>
<td width="171" height="9"><b><font face="Optima-Bold" size="1">
<td width="111" style="width: 83.0pt; padding: .75pt" height="38">
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Z.
<p align="left">The effects of Belladonna and</font></b> <font face="Optima-Bold" size="1"><b>Ferrum
phosphoricum on the</b></font> <font face="Optima-Bold" size="1"><b>chemoluminescence
Naturtorschung</span></i><span style="font-size:7.5pt;font-family:Optima">,<o:p>
</o:p>
of human</b></font> <b><font face="Optima-Bold" size="1">poly-morphonuclear
neutrophils</font></b></p>
<br>
</span><b><span style="font-size:7.5pt;font-family:Optima-Bold">1975</span></b><span style="font-size:7.5pt;font-family:Optima">,
</td>
30:<br>
<td width="128" height="9"><font face="Optima" size="1">
<p align="left">Poitevin B.,</p>
643-649.</span></p>
</td>
<p align="left">Aubin M.,</p>
<td width="90" style="width: 67.45pt; padding: .75pt" height="38">
<p align="left">Royer J.F.</font></p>
<p style="mso-line-height-alt:6.75pt"><b><span style="font-size:7.5pt;
</td>
font-family:Optima-Bold">Inhibitory</span></b></p>
<td width="84" height="9"><i><font face="Optima-Oblique" size="1">
</td>
<p align="left">Ann. Homéop. Fr.</font></i><font face="Optima" size="1">,</p>
<td width="84" style="width: 62.9pt; padding: .75pt" height="38">
</font><b><font face="Optima-Bold" size="1">
<p align="left">1983</font></b><font face="Optima" size="1">, 3: 5-12.</font></p>
<p><span style="font-size:7.5pt;font-family:Optima">Lymphocyte<o:p>
</td>
</o:p>
<td width="92" height="9"><b>
</span></p>
<p align="left"><font face="Optima-Bold" size="1">Inhibitory</font></b></p>
<p style="mso-line-height-alt:6.75pt"><span style="font-size:7.5pt;
font-family:Optima">growth</span></p>
</td>
</td>
<td width="203" height="9"><font face="Optima" size="1">Radical release</font></td>
</tr>
</tr>
<tr style="height:6.75pt">
<tr>
<td width="171" height="8"><b><font face="Optima-Bold" size="1">
<td width="162" style="width: 121.6pt; padding: .75pt" height="47">
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">The effects of
<p align="left">Effect of aconitum and veratrum</p>
Belladonna and</span></b> <b><span style="font-size:7.5pt;font-family:Optima-Bold">Ferrum
<p align="left">on the isolated perfused heart of</p>
<p align="left">the common eel </font></b><font face="Optima" size="1">(Anguilla
phosphoricum on the</span></b> <b><span style="font-size:7.5pt;font-family:
Optima-Bold">chemoluminescence of human</span></b> <b><span style="font-size:
anguilla)</font></p>
7.5pt;font-family:Optima-Bold">poly-morphonuclear neutrophils</span></b></p>
</td>
</td>
<td width="128" height="8"><font face="Optima" size="1">
<td width="121" style="width: 91.05pt; padding: .75pt" height="47"><span style="font-size: 7.5pt; font-family: Optima">Poitevin B.,<br>
<p align="left">Pennec J.P.,</p>
<p align="left">Aubin M.</font></p>
Aubin M.,<br>
</td>
Royer J.F.</span></td>
<td width="84" height="8"><i><font face="Optima-Oblique" size="1">
<td width="111" style="width: 83.0pt; padding: .75pt" height="47">
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Ann. Homéop.
<p align="left">Comp. Biochem.</p>
<p align="left">Physiol.</font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">1984</font></b><font face="Optima" size="1">,</p>
Fr.</span></i><span style="font-size:7.5pt;font-family:Optima">,<o:p>
<p align="left">776: 367-369.</font></p>
</o:p>
</td>
</span></p>
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Protective</font></b></td>
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">1983</span></b><span style="font-size:7.5pt;font-family:Optima">,
3: 5-12.</span></p>
<td width="203" height="8"><font face="Optima" size="1">Aconitine toxicity</font></td>
</tr>
</td>
<td width="90" style="width: 67.45pt; padding: .75pt" height="47">
<tr>
<td width="171" height="8"><b><font face="Optima-Bold" size="1">
<p style="mso-line-height-alt:6.75pt"><b><span style="font-size:7.5pt;
font-family:Optima-Bold">Inhibitory</span></b></p>
<p align="left">Elements of homeopathic</p>
</td>
<p align="left">pharmacology</font></b></p>
<td width="84" style="width: 62.9pt; padding: .75pt" height="47">
</td>
<td width="128" height="8"><font face="Optima" size="1">
<p class="MsoNormal" style="mso-line-height-alt:6.75pt"><span style="font-size:
<p align="left">Aubin M.</font></p>
7.5pt;font-family:Optima">Radical release</span></p>
</td>
</td>
</tr>
<td width="84" height="8"><i><font face="Optima-Oblique" size="1">
<tr style="height:6.0pt">
<p align="left">Homéopathie</p>
<td width="162" style="width: 121.6pt; padding: .75pt" height="29">
<p align="left">Franç.</font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">1984</font></b><font face="Optima" size="1">,
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Effect of
72:</p>
aconitum and veratrum on the isolated perfused heart of the common eel </span></b><span style="font-size:7.5pt;font-family:Optima">(Anguilla
<p align="left">231- 235</font></p>
</td>
anguilla)</span></p>
</td>
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Protective</font></b></td>
<td width="203" height="8"><font face="Optima" size="1">Aconitine toxicity</font></td>
<td width="121" style="width: 91.05pt; padding: .75pt" height="29"><span style="font-size: 7.5pt; font-family: Optima">Pennec J.P.,<br>
</tr>
Aubin M.</span></td>
<td width="111" style="width: 83.0pt; padding: .75pt" height="29">
<tr>
<td width="171" height="8"><b><font face="Optima-Bold" size="1">
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Comp.
Biochem.<o:p>
<p align="left">The effect of homeopathic</p>
</o:p>
<p align="left">preparations on the phagocyte</p>
<br>
<p align="left">activity of granulocytes. In vitro</p>
Physiol.</span></i><span style="font-size:7.5pt;font-family:Optima">, </span><b><span style="font-size:7.5pt;font-family:Optima-Bold">1984</span></b><span style="font-size:7.5pt;font-family:Optima">,</span><span style="font-size: 7.5pt; font-family: Optima"><br>
<p align="left">tests and double-blind controlled</p>
776: 367-369.<br>
<p align="left">trials</font></b></p>
</td>
</span></p>
</td>
<td width="128" height="8"><font face="Optima" size="1">
<td width="90" style="width: 67.45pt; padding: .75pt" height="29">
<p align="left">Wagner H.,</p>
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Protective</span></b></p>
<p align="left">Jurcic K.,</p>
</td>
<p align="left">Doenicke A.,</p>
<td width="84" style="width: 62.9pt; padding: .75pt" height="29">
<p align="left">Rosenhuber E.,</p>
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><span style="font-size:
<p align="left">Behrens N.</font></p>
7.5pt;font-family:Optima">Aconitine toxicity</span></p>
</td>
</td>
<td width="84" height="8"><i><font face="Optima-Oblique" size="1">
</tr>
<p align="left">Arzneim.</p>
<tr style="height:6.0pt">
<p align="left">Forsch./Drug Res.</font></i><font face="Optima" size="1">,</p>
<td width="162" style="width: 121.6pt; padding: .75pt" height="7">
</font><b><font face="Optima-Bold" size="1">
<p align="left">1986</font></b><font face="Optima" size="1">, 36:</p>
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Elements of
<p align="left">1424-1425.</font></p>
homeopathic pharmacology</span></b></p>
</td>
</td>
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Stimulant</font></b></td>
<td width="121" style="width: 91.05pt; padding: .75pt" height="7">
<td width="203" height="8"><font face="Optima" size="1">Phagocytosis</font></td>
<p><span style="font-size:7.5pt;font-family:Optima">Aubin M.</span></p>
</tr>
</td>
<td width="111" style="width: 83.0pt; padding: .75pt" height="7">
<tr>
<td width="171" height="8"><b><font face="Optima-Bold" size="1">
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Homéopathie
Franç.</span></i><span style="font-size:7.5pt;font-family:Optima">, </span><b><span style="font-size:7.5pt;font-family:Optima-Bold">1984</span></b><span style="font-size:7.5pt;font-family:Optima">,
<p align="left">Approach to quantitative analysis</p>
72:231- 235</span></p>
<p align="left">of the effect of Apis mellifica on</p>
</td>
<p align="left">the degranulation of human</p>
<td width="90" style="width: 67.45pt; padding: .75pt" height="7">
<p align="left">basophils cultivated in vitro</font></b></p>
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Protective</span></b></p>
</td>
</td>
<td width="128" height="8"><font face="Optima" size="1">
<td width="84" style="width: 62.9pt; padding: .75pt" height="7">
<p align="left">Poitevin B.,</p>
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><span style="font-size:
<p align="left">Aubin M.,</p>
<p align="left">Benveniste J.</font></p>
7.5pt;font-family:Optima">Aconitine toxicity</span></p>
</td>
</td>
</tr>
<td width="84" height="8"><i><font face="Optima-Oblique" size="1">
<tr style="height:6.0pt">
<p align="left">Innov. Tech. Biol.</p>
<td width="162" style="width: 121.6pt; padding: .75pt" height="25">
<p align="left">Med.</font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">1986</font></b><font face="Optima" size="1">,
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">The effect of
7:</p>
homeopathic preparations on the phagocyte activity of granulocytes. In
<p align="left">64-68.</font></p>
vitro tests and double-blind controlled trials</span></b></p>
</td>
</td>
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Inhibitory</font></b></td>
<td width="203" height="8"><font face="Optima" size="1">
<td width="121" style="width: 91.05pt; padding: .75pt" height="25"><span style="font-size: 7.5pt; font-family: Optima">Wagner H.,<br>
<p align="left">Basophil</p>
Jurcic K.,<br>
Doenicke A.,<br>
<p align="left">degranulation</font></p>
</td>
Rosenhuber E.,<br>
</tr>
Behrens N.</span></td>
<td width="111" style="width: 83.0pt; padding: .75pt" height="25">
<tr>
<td width="171" height="8"><b><font face="Optima-Bold" size="1">
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Arzneim.<br>
Forsch./Drug Res.,<br>
<p align="left">In vitro stimulation of human</font></b> <b><font face="Optima-Bold" size="1">granulocytes
and lymphocytes by</font></b> <font face="Optima-Bold" size="1"><b>pico-
</span></i><b><span style="font-size:7.5pt;font-family:Optima-Bold">1986</span></b><span style="font-size:7.5pt;font-family:Optima">,
and femtogram quantities of</b></font> <b><font face="Optima-Bold" size="1">cytostatic
</span><span style="font-size: 7.5pt; font-family: Optima">36:<br>
agents</font></b></p>
1424-1425.</span></p>
</td>
</td>
<td width="128" height="8"><font face="Optima" size="1">
<td width="90" style="width: 67.45pt; padding: .75pt" height="25">
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Stimulant</span></b></p>
<p align="left">Wagner H.,</p>
</td>
<p align="left">Kreher B.,</p>
<td width="84" style="width: 62.9pt; padding: .75pt" height="25">
<p align="left">Jurcic K.</font></p>
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><span style="font-size:
</td>
7.5pt;font-family:Optima">Phagocytosis</span></p>
<td width="84" height="8"><font face="Optima-Oblique" size="1"><i>
</td>
<p align="left">Arzneim.</i></font> <b><font face="Optima-Oblique" size="1"><i>Forsch./Drug
</tr>
Res.</i></font><font face="Optima" size="1">,</font></b> <b><font face="Optima-Bold" size="1">1988</font><font face="Optima" size="1">,
<tr style="height:6.0pt">
38:</font></b> <b><font face="Optima" size="1">273-275.</font></b></p>
<td width="162" style="width: 121.6pt; padding: .75pt" height="20">
</td>
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Stimulant</font></b></td>
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Approach to
quantitative analysis of the effect of Apis mellifica on the degranulation
<td width="203" height="8"><font face="Optima" size="1">
<p align="left">Lymphocyte</p>
of human basophils cultivated in vitro</span></b></p>
</td>
<p align="left">growth</font></p>
<td width="121" style="width: 91.05pt; padding: .75pt" height="20"><span style="font-size: 7.5pt; font-family: Optima">Poitevin B.,<br>
</td>
</tr>
Aubin M.,<br>
Benveniste J.</span></td>
<tr>
<td width="171" height="8"><b><font face="Optima-Bold" size="1">
<td width="111" style="width: 83.0pt; padding: .75pt" height="20">
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Innov.
<p align="left">Human basophil degranulation</font></b> <b><font face="Optima-Bold" size="1">triggered
Tech. Biol.<br>
by very dilute antiserum</font></b> <b><font face="Optima-Bold" size="1">against
Med.</span></i><span style="font-size:7.5pt;font-family:Optima">, </span><b><span style="font-size:7.5pt;font-family:Optima-Bold">1986</span></b><span style="font-size:7.5pt;font-family:Optima">,
IgE</font></b></p>
</span><span style="font-size: 7.5pt; font-family: Optima">7:<br>
</td>
64-68.</span></p>
<td width="128" height="8"><font face="Optima" size="1">
</td>
<p align="left">Davenas E.,</font> <font face="Optima" size="1"><b>Beauvais
<td width="90" style="width: 67.45pt; padding: .75pt" height="20">
F.,</b></font> <font face="Optima" size="1"><b>Amara J.,</b></font> <font face="Optima" size="1"><b>Robinson
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Inhibitory</span></b></p>
M.,</b></font> <font face="Optima" size="1"><b>Miadonna A.,</b></font> <font face="Optima" size="1"><b>Tedeschi
</td>
A.,</b></font> <font face="Optima" size="1"><b>Pomeranz B.,</b></font> <font face="Optima" size="1"><b>Fortner
<td width="84" style="width: 62.9pt; padding: .75pt" height="20">
P.,</b></font> <font face="Optima" size="1"><b>Belon P.,</b></font> <font face="Optima" size="1"><b>Sainte-Laudy
<p><span style="font-size:7.5pt;font-family:Optima">Basophil<o:p>
J.,</b></font> <font face="Optima" size="1"><b>Poitevin B.,</b></font> <b><font face="Optima" size="1">Benveniste
J.</font></b></p>
</o:p>
</td>
</span></p>
<td width="84" height="8"><i><font face="Optima-Oblique" size="1">
<p style="mso-line-height-alt:6.0pt"><span style="font-size:7.5pt;font-family:
Optima">degranulation</span></p>
<p align="left">Nature</font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">1988</font></b><font face="Optima" size="1">,</p>
</td>
<p align="left">333: 816-818.</font></p>
</td>
</tr>
<tr style="height:6.0pt">
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Stimulant</font></b></td>
<td width="203" height="8"><font face="Optima" size="1">
<td width="162" style="width: 121.6pt; padding: .75pt" height="1">
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">In vitro
<p align="left">Basophils</font></p>
stimulation of human</span></b> <b><span style="font-size:7.5pt;font-family:
</td>
Optima-Bold">granulocytes and lymphocytes by</span></b> <b><span style="font-size:7.5pt;font-family:Optima-Bold">pico-
</tr>
and femtogram quantities of</span></b> <b><span style="font-size:7.5pt;font-family:Optima-Bold">cytostatic
<tr>
agents</span></b></p>
<td width="171" height="8"><font face="Optima" size="1">
</td>
<p align="left"></font><b><font face="Optima-Bold" size="1">In vitro
<td width="121" style="width: 91.05pt; padding: .75pt" height="1"><span style="font-size: 7.5pt; font-family: Optima">Wagner H.,<br>
immunological</p>
Kreher B.,<br>
<p align="left">degranulation of human basophils</p>
Jurcic K.</span></td>
<p align="left">is modulated by lung histamine</p>
<td width="111" style="width: 83.0pt; padding: .75pt" height="1">
<p align="left">and Apis mellifica</font></b></p>
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Arzneim.</span></i>
</td>
<b><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Forsch./Drug
<td width="128" height="8"><font face="Optima" size="1">
Res.</span></i><span style="font-size:7.5pt;font-family:Optima">,</span></b>
<p align="left">Poitevin B.,</p>
<b><span style="font-size:7.5pt;font-family:Optima-Bold">1988</span><span style="font-size:7.5pt;font-family:Optima">,
<p align="left">Davenas E.,</p>
<p align="left">Benveniste J.</font></p>
38:</span></b> <b><span style="font-size:7.5pt;font-family:Optima">273-275.</span></b></p>
</td>
</td>
<td width="84" height="8"><i><font face="Optima-Oblique" size="1">
<td width="90" style="width: 67.45pt; padding: .75pt" height="1">
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Stimulant</span></b></p>
<p align="left">Brit. J. Clin.</p>
</td>
<p align="left">Pharmacol.</font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">1988</font></b><font face="Optima" size="1">,</p>
<td width="84" style="width: 62.9pt; padding: .75pt" height="1">
<p align="left">25: 439-444.</font></p>
<p><span style="font-size:7.5pt;font-family:Optima">Lymphocyte<o:p>
</td>
</o:p>
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Inhibitory</font></b></td>
</span></p>
<td width="203" height="8"><font face="Optima" size="1">
<p style="mso-line-height-alt:6.0pt"><span style="font-size:7.5pt;font-family:
<p align="left">Basophil</p>
<p align="left">degranulation</font></p>
Optima">growth</span></p>
</td>
</td>
</tr>
</tr>
<tr>
<tr style="height:6.0pt">
<td width="171" height="8"><b><font face="Optima-Bold" size="1">
<td width="162" style="width: 121.6pt; padding: .75pt" height="89">
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Human basophil
<p align="left">Cytotoxic agents as</p>
degranulation</span></b> <b><span style="font-size:7.5pt;font-family:Optima-Bold">triggered
<p align="left">immunomodulators</font></b></p>
by very dilute antiserum</span></b> <b><span style="font-size:7.5pt;
</td>
font-family:Optima-Bold">against IgE</span></b></p>
<td width="128" height="8"><font face="Optima" size="1">
</td>
<p align="left">Wagner H.,</p>
<td width="121" style="width: 91.05pt; padding: .75pt" height="89">
<p align="left">Kreher B.</font></p>
<p><span style="font-size:7.5pt;font-family:Optima">Davenas E.,</span> <span style="font-size:7.5pt;font-family:Optima">Beauvais
</td>
<td width="84" height="8"><i><font face="Optima-Oblique" size="1">
F.,</span> <span style="font-size:7.5pt;font-family:Optima">Amara J.,</span>
<span style="font-size:7.5pt;font-family:Optima">Robinson M.,</span> <span style="font-size:7.5pt;font-family:Optima">Miadonna
<p align="left">Proc. of the 3rd</p>
<p align="left">GIRI meeting</font></i><font face="Optima" size="1">,</p>
A.,</span> <span style="font-size:7.5pt;font-family:Optima">Tedeschi A.,</span>
<p align="left">Paris, </font><b><font face="Optima-Bold" size="1">1989</font></b><font face="Optima" size="1">,
<span style="font-size:7.5pt;font-family:Optima">Pomeranz B.,</span> <span style="font-size:7.5pt;font-family:Optima">Fortner
P.,</span> <span style="font-size:7.5pt;font-family:Optima">Belon P.,</span>
31-</p>
<span style="font-size:7.5pt;font-family:Optima">Sainte-Laudy J.,</span> <span style="font-size:7.5pt;font-family:Optima">Poitevin
<p align="left">46.</font></p>
B.,</span> <span style="font-size:7.5pt;font-family:Optima">Benveniste J.</span></p>
</td>
</td>
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Stimulant</font></b></td>
<td width="203" height="8"><font face="Optima" size="1">
<td width="111" style="width: 83.0pt; padding: .75pt" height="89">
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Nature</span></i><span style="font-size:7.5pt;font-family:Optima">,
<p align="left">Lymphocyte</p>
</span><b><span style="font-size:7.5pt;font-family:Optima-Bold">1988</span></b><span style="font-size:7.5pt;font-family:Optima">,<o:p>
<p align="left">growth</font></p>
</td>
</o:p>
</tr>
</span></p>
<p><span style="font-size:7.5pt;font-family:Optima">333: 816-818.</span></p>
<tr>
</td>
<td width="171" height="8"><b><font face="Optima-Bold" size="1">
<td width="90" style="width: 67.45pt; padding: .75pt" height="89">
<p align="left">Contributions of fundamental</p>
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Stimulant</span></b></p>
<p align="left">research in homeopathy</font></b></p>
</td>
</td>
<td width="128" height="8"><font face="Optima" size="1">
<td width="84" style="width: 62.9pt; padding: .75pt" height="89">
<p style="mso-line-height-alt:6.0pt"><span style="font-size:7.5pt;font-family:
<p align="left">Boiron J.,</p>
<p align="left">Belon P.</font></p>
Optima">Basophils</span></p>
</td>
</td>
</tr>
<td width="84" height="8"><i><font face="Optima-Oblique" size="1">
<tr style="height:6.0pt">
<p align="left">Berl. J. Res. Hom.</font></i><font face="Optima" size="1">,</p>
<td width="162" style="width: 121.6pt; padding: .75pt" height="30">
</font><b><font face="Optima-Bold" size="1">
<p align="left">1990</font></b><font face="Optima" size="1">, 1: 34-35.</font></p>
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">In vitro
immunological degranulation of human basophils is modulated by lung
</td>
histamine and Apis mellifica</span></b></p>
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Inhibitory</font></b></td>
</td>
<td width="203" height="8"><font face="Optima" size="1">
<td width="121" style="width: 91.05pt; padding: .75pt" height="30"><span style="font-size: 7.5pt; font-family: Optima">Poitevin B.,<br>
<p align="left">Basophil</p>
Davenas E.,<br>
<p align="left">degranulation</font></p>
</td>
Benveniste J.</span></td>
<td width="111" style="width: 83.0pt; padding: .75pt" height="30">
</tr>
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Brit. J. Clin.<br>
<tr>
Pharmacol.</span></i><span style="font-size:7.5pt;font-family:Optima">, </span><b><span style="font-size:7.5pt;font-family:Optima-Bold">1988</span></b><span style="font-size:7.5pt;font-family:Optima">,<br>
<td width="171" height="8"><b><font face="Optima-Bold" size="1">
25: 439-444.</span></p>
<p align="left">Synergism of action between</p>
</td>
<p align="left">indoleacetic acid (IAA) and highly</p>
<td width="90" style="width: 67.45pt; padding: .75pt" height="30">
<p align="left">diluted solutions of CaCO3 on the</p>
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Inhibitory</span></b></p>
<p align="left">growth of oat coleoptiles</font></b></p>
</td>
</td>
<td width="128" height="8"><font face="Optima" size="1">Bornoroni C.</font></td>
<td width="84" style="width: 62.9pt; padding: .75pt" height="30"><span style="font-size: 7.5pt; font-family: Optima">Basophil<br>
degranulation</span></td>
<td width="84" height="8"><i><font face="Optima-Oblique" size="1">
</tr>
<p align="left">Berl. J. Res. Hom.</font></i><font face="Optima" size="1">,</p>
<tr style="height:6.0pt">
</font><b><font face="Optima-Bold" size="1">
<td width="162" style="width: 121.6pt; padding: .75pt" height="1">
<p align="left">1991</font></b><font face="Optima" size="1">, 1 (4/5):</p>
<p align="left">275-278.</font></p>
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Cytotoxic
agents as immunomodulators</span></b></p>
</td>
</td>
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Stimulant</font></b></td>
<td width="203" height="8"><font face="Optima" size="1">
<td width="121" style="width: 91.05pt; padding: .75pt" height="1"><span style="font-size: 7.5pt; font-family: Optima">Wagner H.,<br>
<p align="left">Growth of plant</p>
Kreher B.</span></td>
<td width="111" style="width: 83.0pt; padding: .75pt" height="1">
<p align="left">cells</font></p>
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Proc. of
</td>
</tr>
the 3rd<br>
GIRI meetin</span></i><span style="font-size:7.5pt;font-family:Optima">g,<br>
<tr>
<td width="171" height="8"><b><font face="Optima-Bold" size="1">
Paris, </span><b><span style="font-size:7.5pt;font-family:Optima-Bold">1989</span></b><span style="font-size:7.5pt;font-family:Optima">,
</span><span style="font-size: 7.5pt; font-family: Optima">31-<br>
<p align="left">Study of the action of</p>
<p align="left">Hahnemannian dilutions of</p>
46.</span></p>
</td>
<p align="left">mercury chloride on the mitotic</p>
<td width="90" style="width: 67.45pt; padding: .75pt" height="1">
<p align="left">index in animal cell cultures.</font></b></p>
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Stimulant</span></b></p>
</td>
</td>
<td width="128" height="8"><font face="Optima" size="1">
<td width="84" style="width: 62.9pt; padding: .75pt" height="1">
<p align="left">Boiron J.,</p>
<p align="left">Abecassis J.,</p>
<p><span style="font-size:7.5pt;font-family:Optima">Lymphocyte<o:p>
<p align="left">Cotte J.,</p>
</o:p>
<p align="left">Bernard A.M.</font></p>
</span></p>
<p style="mso-line-height-alt:6.0pt"><span style="font-size:7.5pt;font-family:
</td>
Optima">growth</span></p>
<td width="84" height="8"><i><font face="Optima-Oblique" size="1">
</td>
<p align="left">Ann. Homéop.</p>
</tr>
<p align="left">Fr</font></i><font face="Optima" size="1">., </font><b><font face="Optima-Bold" size="1">1991</font></b><font face="Optima" size="1">,
<tr style="height:6.0pt">
23:</p>
<td width="162" style="width: 121.6pt; padding: .75pt" height="15">
<p align="left">43-49.</font></p>
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Contributions
</td>
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Protective</font></b></td>
of fundamental research in homeopathy</span></b></p>
</td>
<td width="203" height="8"><font face="Optima" size="1">Hg toxicity</font></td>
<td width="121" style="width: 91.05pt; padding: .75pt" height="15"><span style="font-size: 7.5pt; font-family: Optima">Boiron J.,<br>
</tr>
<tr>
Belon P.</span></td>
<td width="171" height="8"><b><font face="Optima-Bold" size="1">
<td width="111" style="width: 83.0pt; padding: .75pt" height="15">
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Berl. J.
<p align="left">Dual effects of formylpeptides on</p>
Res. Hom.,<br>
<p align="left">the adhesion of endotoxin-primed</p>
</span></i><b><span style="font-size:7.5pt;font-family:Optima-Bold">1990</span></b><span style="font-size:7.5pt;font-family:Optima">,
<p align="left">human neutrophils</font></b></p>
</td>
1: 34-35.</span></p>
</td>
<td width="128" height="8"><font face="Optima" size="1">
<td width="90" style="width: 67.45pt; padding: .75pt" height="15">
<p align="left">Bellavite P.,</p>
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Inhibitory</span></b></p>
<p align="left">Chirumbolo S.,</p>
</td>
<p align="left">Lippi G.,</p>
<td width="84" style="width: 62.9pt; padding: .75pt" height="15"><span style="font-size: 7.5pt; font-family: Optima">Basophil<br>
<p align="left">Andrioli G.,</p>
<p align="left">Bonazzi L.,</p>
degranulation</span></td>
</tr>
<p align="left">Ferro I.</font></p>
<tr style="height:6.0pt">
</td>
<td width="84" height="8"><i><font face="Optima-Oblique" size="1">
<td width="162" style="width: 121.6pt; padding: .75pt" height="13">
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Synergism of
<p align="left">Cell. Biochem.</p>
action between indoleacetic acid (IAA) and highlydiluted solutions of
<p align="left">Funct.</font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">1993</font></b><font face="Optima" size="1">,
11:</p>
CaCO3 on the growth of oat coleoptiles</span></b></p>
</td>
<p align="left">231-239.</font></p>
<td width="121" style="width: 91.05pt; padding: .75pt" height="13">
</td>
<p class="MsoNormal"><span style="font-size:7.5pt;font-family:Optima">Bornoroni
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Inhibitory</font></b></td>
C.</span></p>
<td width="203" height="8"><font face="Optima" size="1">
</td>
<p align="left">Cell adhesion</p>
<td width="111" style="width: 83.0pt; padding: .75pt" height="13">
<p align="left">(bact. pept.</p>
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Berl. J.
<p align="left">10-8-10-9)</font></p>
Res. Hom.,</span></i><b><span style="font-size:7.5pt;font-family:Optima-Bold"><br>
</td>
1991</span></b><span style="font-size:7.5pt;font-family:Optima">, 1 (4/5):
</tr>
<tr>
275-278.</span></p>
</td>
<td width="171" height="8"><b><font face="Optima-Bold" size="1">
<td width="90" style="width: 67.45pt; padding: .75pt" height="13">
<p align="left">Effects of homeopathic</p>
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Stimulant</span></b></p>
<p align="left">preparations of organic acids and</p>
</td>
<p align="left">of minerals on the oxidative</p>
<td width="84" style="width: 62.9pt; padding: .75pt" height="13">
<p align="left">metabolism of human neutrophils</font></b></p>
<p><span style="font-size:7.5pt;font-family:Optima">Growth of plant </span><span style="font-size:7.5pt;font-family:
</td>
Optima">cells</span></p>
<td width="128" height="8"><font face="Optima" size="1">
</td>
<p align="left">Chirumbolo S.,</p>
</tr>
<p align="left">Signorini A.,</p>
<tr style="height:6.0pt">
<p align="left">Bianchi I.,</p>
<td width="162" style="width: 121.6pt; padding: .75pt" height="23">
<p align="left">Lippi G.,</p>
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Study of the
<p align="left">Bellavite P.</font></p>
action of Hahnemannian dilutions of mercury chloride on the mitotic index
</td>
in animal cell cultures.</span></b></p>
<td width="84" height="8"><i><font face="Optima-Oblique" size="1">
</td>
<p align="left">Br. Hom. J.</font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">1993</font></b><font face="Optima" size="1">,</p>
<td width="121" style="width: 91.05pt; padding: .75pt" height="23"><span style="font-size: 7.5pt; font-family: Optima">Boiron J.,<br>
<p align="left">82: 227-244.</font></p>
</td>
Abecassis J.,<br>
Cotte J.,<br>
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Inhibitory</font></b></td>
Bernard A.M.</span></td>
<td width="203" height="8"><font face="Optima" size="1">
<td width="111" style="width: 83.0pt; padding: .75pt" height="23">
<p align="left">Leucocyte</p>
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Ann. Homé</span></i><i><span style="font-size:7.5pt;font-family:Optima-Oblique">op.Fr</span></i><span style="font-size:7.5pt;font-family:Optima">.,
<p align="left">activation</p>
</span><b><span style="font-size:7.5pt;font-family:Optima-Bold">1991</span></b><span style="font-size:7.5pt;font-family:Optima">,
<p align="left">(metabolism)</font></p>
</td>
23:<o:p>
</tr>
</o:p>
<tr>
</span></p>
<p><span style="font-size:7.5pt;font-family:Optima">43-49.</span></p>
<td width="171" height="8"><b><font face="Optima-Bold" size="1">
</td>
<p align="left">Platelets/endothelial cells</p>
<td width="90" style="width: 67.45pt; padding: .75pt" height="23">
<p align="left">interactions in presence of</p>
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Protective</span></b></p>
<p align="left">acetylsalicylic acid at ultra low</p>
</td>
<p align="left">dose</font></b></p>
<td width="84" style="width: 62.9pt; padding: .75pt" height="23">
</td>
<td width="128" height="8"><font face="Optima" size="1">
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><span style="font-size:
7.5pt;font-family:Optima">Hg toxicity</span></p>
<p align="left">Doutremepuich</p>
<p align="left">C.,</p>
</td>
</tr>
<p align="left">Lalanne M.C.,</p>
<tr style="height:6.0pt">
<p align="left">Ramboer I.,</p>
<td width="162" style="width: 121.6pt; padding: .75pt" height="48">
<p align="left">Sertillanges</p>
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Dual effects
<p align="left">M.N.,</p>
of formylpeptides on the adhesion of endotoxin-primed human neutrophils</span></b></p>
<p align="left">De Seze O.</font></p>
</td>
</td>
<td width="84" height="8"><i><font face="Optima-Oblique" size="1">
<td width="121" style="width: 91.05pt; padding: .75pt" height="48"><span style="font-size: 7.5pt; font-family: Optima">Bellavite P.,<br>
Chirumbolo S.,<br>
<p align="left">Omeomed 92 (C.</p>
Lippi G.,<br>
<p align="left">Bornoroni, ed.)</font></i><font face="Optima" size="1">,</p>
Andrioli G.,<br>
</font><b><font face="Optima-Bold" size="1">
Bonazzi L.,<br>
<p align="left">1993</font></b><font face="Optima" size="1">, Editrice</p>
<p align="left">Compositori,</p>
Ferro I.</span></td>
<td width="111" style="width: 83.0pt; padding: .75pt" height="48">
<p align="left">Bologna:</p>
<p align="left">109-115.</font></p>
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Cell. Biochem.<br>
Funct.</span></i><span style="font-size:7.5pt;font-family:Optima">, </span><b><span style="font-size:7.5pt;font-family:Optima-Bold">1993</span></b><span style="font-size:7.5pt;font-family:Optima">,
</td>
11: 231-239.</span></p>
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Inhibitory</font></b></td>
</td>
<td width="203" height="8"><font face="Optima" size="1">
<td width="90" style="width: 67.45pt; padding: .75pt" height="48">
<p align="left">Prostacyclin</p>
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Inhibitory</span></b></p>
<p align="left">release</font></p>
</td>
</td>
<td width="84" style="width: 62.9pt; padding: .75pt" height="48">
</tr>
<p class="MsoNormal"><span style="font-size:7.5pt;mso-bidi-font-size:12.0pt;font-family:&quot;Times New Roman&quot;;
<tr>
mso-fareast-font-family:&quot;Times New Roman&quot;;mso-ansi-language:EN-GB;mso-fareast-language:
<td width="171" height="8"><b><font face="Optima-Bold" size="1">
EN-US;mso-bidi-language:AR-SA">Cell adhesion<br>
<p align="left">Effect of high dilutions of epidermal</p>
(bact. pept.<br>
<p align="left">growth factor (EGF) on </font><i><font face="Optima-BoldOblique" size="1">in
10<sup>-8</sup>-10<sup>-9</sup>)</span></td>
vitro</p>
</tr>
</font></i><font face="Optima-Bold" size="1">
<tr style="height:6.0pt">
<p align="left">proliferation of keratinocyte and</p>
<td width="162" style="width: 121.6pt; padding: .75pt" height="23">
<p align="left">fibroblast cell lines</font></b></p>
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Effects of
</td>
homeopathic preparations of organic acids and of minerals on the oxidative
<td width="128" height="8"><font face="Optima" size="1">
<p align="left">Fougeray S.,</p>
metabolism of human neutrophils</span></b></p>
</td>
<p align="left">Moubry K.,</p>
<td width="121" style="width: 91.05pt; padding: .75pt" height="23"><span style="font-size: 7.5pt; font-family: Optima">Chirumbolo S.,<br>
<p align="left">Vallot N.,</p>
Signorini A.,<br>
<p align="left">Bastide M.</font></p>
</td>
Bianchi I.,<br>
Lippi G.,<br>
<td width="84" height="8"><i><font face="Optima-Oblique" size="1">
Bellavite P.</span></td>
<p align="left">Br. Hom. J.</font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">1993</font></b><font face="Optima" size="1">,</p>
<td width="111" style="width: 83.0pt; padding: .75pt" height="23">
<p align="left">82: 124-125.</font></p>
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Br. Hom. J.</span></i><span style="font-size:7.5pt;font-family:Optima">,
</td>
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Inhibitory</font></b></td>
</span><b><span style="font-size:7.5pt;font-family:Optima-Bold">1993</span></b><span style="font-size:7.5pt;font-family:Optima">,<o:p>
</o:p>
<td width="203" height="8"><font face="Optima" size="1">
<p align="left">Growth of</p>
</span></p>
<p align="left">keratinocytes</font></p>
<p><span style="font-size:7.5pt;font-family:Optima">82: 227-244.</span></p>
</td>
</td>
<td width="90" style="width: 67.45pt; padding: .75pt" height="23">
</tr>
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Inhibitory</span></b></p>
<tr>
</td>
<td width="171" height="8"><b><font face="Optima-Bold" size="1">
<td width="84" style="width: 62.9pt; padding: .75pt" height="23"><span style="font-size: 7.5pt; font-family: Optima">Leucocyte<br>
<p align="left">Effects of different homeopathic</p>
activation<br>
<p align="left">potencies of Lachesis on</p>
(metabolism)</span></td>
<p align="left">lymphocyte cultures obtained</p>
</tr>
<p align="left">from rabbit blood</font></b></p>
<tr style="height:6.0pt">
</td>
<td width="128" height="8"><font face="Optima" size="1">
<td width="162" style="width: 121.6pt; padding: .75pt" height="51">
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Platelets/endothelial
<p align="left">Enbergs H.,</p>
cells interactions in presence of acetylsalicylic acid at ultra low dose</span></b></p>
<p align="left">Arndt G.</font></p>
</td>
</td>
<td width="84" height="8"><i><font face="Optima-Oblique" size="1">
<td width="121" style="width: 91.05pt; padding: .75pt" height="51"><span style="font-size: 7.5pt; font-family: Optima">Doutremepuich<br>
C.,<br>
<p align="left">Biol. Tier., </font><b><font face="Optima-BoldOblique" size="1">1993</font></b><font face="Optima-Oblique" size="1">,</p>
Lalanne M.C.,<br>
<p align="left">4.</font></i></p>
</td>
Ramboer I.,<br>
Sertillanges<br>
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Stimulant</font></b></td>
M.N.,<br>
<td width="203" height="8"><font face="Optima" size="1">
<p align="left">Mitotic and</p>
De Seze O.</span></td>
<td width="111" style="width: 83.0pt; padding: .75pt" height="51">
<p align="left">immunostimulating</p>
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Omeomed 92
<p align="left">activity (bact. pept</p>
(C.<br>
<p align="left">10-5-10-6)</font></p>
Bornoroni, ed.),</span></i><b><span style="font-size:7.5pt;font-family:Optima-Bold"><br>
</td>
1993</span></b><span style="font-size:7.5pt;font-family:Optima">, </span><span style="font-size: 7.5pt; font-family: Optima">Editrice<br>
</tr>
<tr>
Compositori,<br>
Bologna:<br>
<td width="171" height="8"><b><font face="Optima-Bold" size="1">
<p align="left">The effect of homeopathic</p>
109-115.</span></p>
</td>
<p align="left">potencies of housedust mite on</p>
<td width="90" style="width: 67.45pt; padding: .75pt" height="51">
<p align="left">the migration of house-dust sensitive</p>
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Inhibitory</span></b></p>
<p align="left">human leukocytes</font></b></p>
</td>
</td>
<td width="128" height="8"><font face="Optima" size="1">
<td width="84" style="width: 62.9pt; padding: .75pt" height="51">
<p align="left">Gibson S.L.,</p>
<p><span style="font-size:7.5pt;font-family:Optima">Prostacyclin<o:p>
<p align="left">Gibson R.G.</font></p>
</o:p>
</td>
</span></p>
<td width="84" height="8"><i><font face="Optima-Oblique" size="1">
<p style="mso-line-height-alt:6.0pt"><span style="font-size:7.5pt;font-family:
Optima">release</span></p>
<p align="left">Complement.</p>
</td>
<p align="left">Ther. Med.</font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">1996</font></b><font face="Optima" size="1">,</p>
</tr>
<p align="left">4: 169-171.</font></p>
<tr style="height:6.0pt">
</td>
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Stimulant</font></b></td>
<td width="162" style="width: 121.6pt; padding: .75pt" height="29">
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Effect of high
<td width="203" height="8"><font face="Optima" size="1">
dilutions of epidermal growth factor (EGF) on </span><i><span style="font-size:7.5pt;font-family:Optima-BoldOblique">in
<p align="left">Leucocyte</p>
vitro </span></i><span style="font-size:7.5pt;font-family:Optima-Bold">proliferation
<p align="left">chemotaxis</font></p>
of keratinocyte and fibroblast cell lines</span></b></p>
</td>
</tr>
</td>
<td width="121" style="width: 91.05pt; padding: .75pt" height="29"><span style="font-size: 7.5pt; font-family: Optima">Fougeray S.,<br>
<tr>
Moubry K.,<br>
<td width="171" height="8"><b><font face="Optima-Bold" size="1">
Vallot N.,<br>
<p align="left">The effects of Nux vomica</p>
Bastide M.</span></td>
<p align="left">Homaccord and Atropinum comp.</p>
<td width="111" style="width: 83.0pt; padding: .75pt" height="29">
<p align="left">on intestinal activity in vitro</font></b></p>
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Br. Hom. J.</span></i><span style="font-size:7.5pt;font-family:Optima">,
</td>
</span><b><span style="font-size:7.5pt;font-family:Optima-Bold">1993</span></b><span style="font-size:7.5pt;font-family:Optima">,<o:p>
<td width="128" height="8"><font face="Optima" size="1">
<p align="left">Kanui T.I.,</p>
</o:p>
<p align="left">Enbergs H.</font></p>
</span></p>
<p><span style="font-size:7.5pt;font-family:Optima">82: 124-125.</span></p>
</td>
</td>
<td width="84" height="8"><i><font face="Optima-Oblique" size="1">
<td width="90" style="width: 67.45pt; padding: .75pt" height="29">
<p align="left">Biol. Tier.</font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">1996</font></b><font face="Optima" size="1">/1,</p>
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Inhibitory</span></b></p>
<p align="left">43-47.</font></p>
</td>
</td>
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Stimulant</font></b></td>
<td width="84" style="width: 62.9pt; padding: .75pt" height="29">
<td width="203" height="8"><font face="Optima" size="1">
<p><span style="font-size:7.5pt;font-family:Optima">Growth of<o:p>
<p align="left">Contraction of</p>
</o:p>
<p align="left">intestinal muscles</font></p>
</span></p>
<p style="mso-line-height-alt:6.0pt"><span style="font-size:7.5pt;font-family:
</td>
Optima">keratinocytes</span></p>
</tr>
<tr>
</td>
</tr>
<td width="171" height="8"><b><font face="Optima-Bold" size="1">
<tr style="height:6.0pt">
<p align="left">Application of flow cytometry to</p>
<td width="162" style="width: 121.6pt; padding: .75pt" height="26">
<p align="left">the analysis of the</p>
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Effects of
<p align="left">immunosuppressive effect of</p>
different homeopathic potencies of Lachesis on lymphocyte cultures
<p align="left">histamine dilutions on human</p>
obtained from rabbit blood</span></b></p>
<p align="left">basophil action: effect of</p>
</td>
<p align="left">cimetidine</font></b></p>
<td width="121" style="width: 91.05pt; padding: .75pt" height="26"><span style="font-size: 7.5pt; font-family: Optima">Enbergs H.,<br>
</td>
Arndt G.</span></td>
<td width="128" height="8"><font face="Optima" size="1">
<td width="111" style="width: 83.0pt; padding: .75pt" height="26">
<p align="left">Sainte-Laudy J.,</p>
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Biol.
<p align="left">Belon P.</font></p>
Tier., </span></i><b><i><span style="font-size:7.5pt;font-family:Optima-BoldOblique">1993</span></i></b><i><span style="font-size:7.5pt;font-family:Optima-Oblique">,
</td>
4.</span></i></p>
<td width="84" height="8"><i><font face="Optima-Oblique" size="1">
</td>
<p align="left">Inflamm. Res</font></i><font face="Optima" size="1">.,</p>
<td width="90" style="width: 67.45pt; padding: .75pt" height="26">
</font><b><font face="Optima-Bold" size="1">
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Stimulant</span></b></p>
<p align="left">1997</font></b><font face="Optima" size="1">, 46:</p>
</td>
<p align="left">S27-S28.</font></p>
<td width="84" style="width: 62.9pt; padding: .75pt" height="26"><span style="font-size: 7.5pt; font-family: Optima">Mitotic and<br>
</td>
immunostimulating<br>
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Inhibitory</font></b></td>
activity (bact. pept<br>
<td width="203" height="8"><font face="Optima" size="1">
</span><span style="font-size:7.5pt;mso-bidi-font-size:12.0pt;font-family:&quot;Times New Roman&quot;;
<p align="left">Basophil</p>
mso-fareast-font-family:&quot;Times New Roman&quot;;mso-ansi-language:EN-GB;mso-fareast-language:
<p align="left">degranulation</font></p>
EN-US;mso-bidi-language:AR-SA">10<sup>-5</sup>-10<sup>-6</sup></span><span style="font-size: 7.5pt; font-family: Optima">)</span></td>
</td>
</tr>
</tr>
<tr>
<tr style="height:6.0pt">
<td width="171" height="8"><b><font face="Optima-Bold" size="1">
<td width="162" style="width: 121.6pt; padding: .75pt" height="40">
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">The effect of
<p align="left">Effects of Podophillum pellatum</p>
homeopathic potencies of housedust mite on the migration of house-dust
<p align="left">compounds in various</p>
sensitive human leukocytes</span></b></p>
<p align="left">preparations and dilutions on</p>
</td>
<p align="left">human neutrophil functions in</p>
<td width="121" style="width: 91.05pt; padding: .75pt" height="40"><span style="font-size: 7.5pt; font-family: Optima">Gibson S.L.,<br>
<p align="left">vitro</font></b></p>
</td>
Gibson R.G.</span></td>
<td width="128" height="8"><font face="Optima" size="1">
<td width="111" style="width: 83.0pt; padding: .75pt" height="40">
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Complement.<br>
<p align="left">Chirumbolo S.,</p>
Ther. Med.</span></i><span style="font-size:7.5pt;font-family:Optima">, </span><b><span style="font-size:7.5pt;font-family:Optima-Bold">1996</span></b><span style="font-size:7.5pt;font-family:Optima">,<br>
<p align="left">Conforti A.,</p>
<p align="left">Lussignoli S.,</p>
4: 169-171.</span></p>
</td>
<p align="left">Metelmann H.</p>
<td width="90" style="width: 67.45pt; padding: .75pt" height="40">
<p align="left">et Al.</font></p>
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Stimulant</span></b></p>
</td>
</td>
<td width="84" height="8"><i><font face="Optima-Oblique" size="1">
<td width="84" style="width: 62.9pt; padding: .75pt" height="40"><span style="font-size: 7.5pt; font-family: Optima">Leucocyte<br>
<p align="left">Br. Hom. J</font></i><font face="Optima" size="1">., </font><b><font face="Optima-Bold" size="1">1997</font></b><font face="Optima" size="1">;</p>
<p align="left">86-16.</font></p>
chemotaxis</span></td>
</td>
</tr>
<tr style="height:6.0pt">
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Inhibitory</font></b></td>
<td width="203" height="8"><font face="Optima" size="1">
<td width="162" style="width: 121.6pt; padding: .75pt" height="20">
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">The effects of
<p align="left">Release of</p>
Nux vomica Homaccord and Atropinum comp. on intestinal activity in vitro</span></b></p>
<p align="left">superoxides</font></p>
</td>
</td>
<td width="121" style="width: 91.05pt; padding: .75pt" height="20"><span style="font-size: 7.5pt; font-family: Optima">Kanui T.I.,<br>
</tr>
<tr>
Enbergs H.</span></td>
<td width="171" height="8"><b><i><font face="Optima-BoldOblique" size="1">
<td width="111" style="width: 83.0pt; padding: .75pt" height="20">
<p align="left">In vivo </font></i><font face="Optima-Bold" size="1">and
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Biol. Tier.</span></i><span style="font-size:7.5pt;font-family:Optima">,
</font><i><font face="Optima-BoldOblique" size="1">in vitro </font></i><font face="Optima-Bold" size="1">studies
</span><b><span style="font-size:7.5pt;font-family:Optima-Bold">1996</span></b><span style="font-size:7.5pt;font-family:Optima">/1,
on the</p>
43-47.</span></p>
</td>
<p align="left">efficiency of potentized and nonpotentized</p>
<td width="90" style="width: 67.45pt; padding: .75pt" height="20">
<p align="left">substances</font></b></p>
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Stimulant</span></b></p>
</td>
</td>
<td width="128" height="8"><font face="Optima" size="1">
<td width="84" style="width: 62.9pt; padding: .75pt" height="20"><span style="font-size: 7.5pt; font-family: Optima">Contraction of<br>
<p align="left">Harisch G.,</p>
<p align="left">Dittmann J.</font></p>
intestinal muscles</span></td>
</td>
</tr>
<tr style="height:6.0pt">
<td width="84" height="8"><i><font face="Optima-Oblique" size="1">
<td width="162" style="width: 121.6pt; padding: .75pt" height="7">
<p align="left">BT, </font></i><b><font face="Optima-Bold" size="1">1997</font></b><font face="Optima" size="1">,
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Application of
2;</p>
flow cytometry to the analysis of the immunosuppressive effect of
<p align="left">40-46.</font></p>
histamine dilutions on human basophil action: effect ofcimetidine</span></b></p>
</td>
</td>
<td width="92" height="8"><font face="Optima" size="1">
<td width="121" style="width: 91.05pt; padding: .75pt" height="7"><span style="font-size: 7.5pt; font-family: Optima">Sainte-Laudy J.,<br>
<p align="left">Difference between</p>
<p align="left">potentised and</p>
Belon P.</span></td>
<td width="111" style="width: 83.0pt; padding: .75pt" height="7">
<p align="left">non-potentised</p>
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Inflamm. Res.,<br>
<p align="left">substances</font></p>
</span></i><b><span style="font-size:7.5pt;font-family:Optima-Bold">1997</span></b><span style="font-size:7.5pt;font-family:Optima">,
</td>
<td width="203" height="8"><i><font face="Optima-Oblique" size="1">
4</span><span style="font-size: 7.5pt; font-family: Optima">6:<br>
S27-S28.</span></p>
<p align="left">In vivo </font></i><font face="Optima" size="1">and </font><i><font face="Optima-Oblique" size="1">in</p>
</td>
<p align="left">vitro </font></i><font face="Optima" size="1">study;
<td width="90" style="width: 67.45pt; padding: .75pt" height="7">
basic</p>
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Inhibitory</span></b></p>
<p align="left">research</font></p>
</td>
</td>
<td width="84" style="width: 62.9pt; padding: .75pt" height="7"><span style="font-size: 7.5pt; font-family: Optima">Basophil<br>
</tr>
degranulation</span></td>
<tr>
</tr>
<td width="171" height="8"><b><font face="Optima-Bold" size="1">
<tr style="height:6.0pt">
<p align="left">Experiments with the effects of</p>
<td width="162" style="width: 121.6pt; padding: .75pt" height="31">
<p align="left">Ubichinon-Injeel and strong</p>
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Effects of
<p align="left">Ubichinon-Injeel on an acellular</p>
Podophillum pellatum compounds in various preparations and dilutions on
<p align="left">system</font></b></p>
human neutrophil functions in vitro</span></b></p>
</td>
</td>
<td width="128" height="8"><font face="Optima" size="1">
<td width="121" style="width: 91.05pt; padding: .75pt" height="31"><span style="font-size: 7.5pt; font-family: Optima">Chirumbolo S.,<br>
<p align="left">Harisch G.,</p>
Conforti A.,<br>
<p align="left">Dittmann J.</font></p>
</td>
Lussignoli S.,<br>
Metelmann H.<br>
<td width="84" height="8"><i><font face="Optima-Oblique" size="1">
et Al.</span></td>
<p align="left">BM, </font></i><b><font face="Optima-Bold" size="1">1997</font></b><font face="Optima" size="1">,
<td width="111" style="width: 83.0pt; padding: .75pt" height="31">
3;</p>
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Br. Hom. J</span></i><span style="font-size:7.5pt;font-family:Optima">.,
<p align="left">99-104.</font></p>
</span><b><span style="font-size:7.5pt;font-family:Optima-Bold">1997</span></b><span style="font-size:7.5pt;font-family:Optima">;<o:p>
</td>
</o:p>
<td width="92" height="8"><font face="Optima" size="1">
<p align="left">Different effects of</p>
</span></p>
<p align="left">associations of</p>
<p><span style="font-size:7.5pt;font-family:Optima">86-16.</span></p>
</td>
<p align="left">various potencies and</p>
<td width="90" style="width: 67.45pt; padding: .75pt" height="31">
<p align="left">individual potencies</font></p>
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Inhibitory</span></b></p>
</td>
</td>
<td width="203" height="8"><i><font face="Optima-Oblique" size="1">
<td width="84" style="width: 62.9pt; padding: .75pt" height="31">
<p align="left">In vitro </font></i><font face="Optima" size="1">study;</p>
<p><span style="font-size:7.5pt;font-family:Optima">Release of<o:p>
<p align="left">basic research</font></p>
</td>
</o:p>
</tr>
</span></p>
<p style="mso-line-height-alt:6.0pt"><span style="font-size:7.5pt;font-family:
<tr>
Optima">superoxides</span></p>
<td width="171" height="8"><b><font face="Optima-Bold" size="1">
</td>
<p align="left">Efficacy of the homeopathic drugs</p>
</tr>
<p align="left">Suis and Arnica comp.-Heel® on</p>
<tr style="height:6.0pt">
<p align="left">lymphocyte and phagocyte</p>
<td width="162" style="width: 121.6pt; padding: .75pt" height="1">
<p align="left">activity</font></b></p>
<p><b><i><span style="font-size:7.5pt;font-family:Optima-BoldOblique">In
</td>
vivo </span></i><span style="font-size:7.5pt;font-family:Optima-Bold">and </span><i><span style="font-size:7.5pt;font-family:Optima-BoldOblique">in
<td width="128" height="8"><font face="Optima" size="1">Enbergs H.</font></td>
<td width="84" height="8"><i><font face="Optima-Oblique" size="1">
vitro </span></i><span style="font-size:7.5pt;font-family:Optima-Bold">studies
on the efficiency of potentized and nonpotentized substances</span></b></p>
<p align="left">BM, </font></i><b><font face="Optima-Bold" size="1">1998</font></b><font face="Optima" size="1">,
1;</p>
</td>
<td width="121" style="width: 91.05pt; padding: .75pt" height="1"><span style="font-size: 7.5pt; font-family: Optima">Harisch G.,<br>
<p align="left">3-11.</font></p>
</td>
Dittmann J.</span></td>
<td width="92" height="8"><font face="Optima" size="1">
<td width="111" style="width: 83.0pt; padding: .75pt" height="1">
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">BT, </span></i><b><span style="font-size:7.5pt;font-family:Optima-Bold">1997</span></b><span style="font-size:7.5pt;font-family:Optima">,
<p align="left">Effect of</p>
2;<o:p>
<p align="left">organotherapeutics</p>
<p align="left">and Arnica comp. -</p>
</o:p>
<p align="left">Heel® on immune</p>
</span></p>
<p align="left">system cells</font></p>
<p><span style="font-size:7.5pt;font-family:Optima">40-46.</span></p>
</td>
</td>
<td width="203" height="8"><i><font face="Optima-Oblique" size="1">
<td width="90" style="width: 67.45pt; padding: .75pt" height="1">
<p align="left">In vitro </font></i><font face="Optima" size="1">study;</p>
<p><span style="font-size:7.5pt;font-family:Optima">Difference between
<p align="left">basic research</font></p>
potentised and non-potentised substances</span></p>
</td>
</td>
<td width="84" style="width: 62.9pt; padding: .75pt" height="1">
</tr>
<p style="mso-line-height-alt:6.0pt"><i><span style="font-size:7.5pt;
<tr>
font-family:Optima-Oblique">In vivo </span></i><span style="font-size:7.5pt;
<td width="171" height="8"><b><font face="Optima-Bold" size="1">
font-family:Optima">and </span><i><span style="font-size:7.5pt;font-family:
<p align="left">Influence of dilutions and</p>
Optima-Oblique">in vitro </span></i><span style="font-size:7.5pt;font-family:
<p align="left">potencies of cAMP on different</p>
<p align="left">enzymatic systems</font></b></p>
Optima">study; basic research</span></p>
</td>
</td>
</tr>
<td width="128" height="8"><font face="Optima" size="1">
<tr style="height:6.0pt">
<p align="left">Harisch G.,</p>
<td width="162" style="width: 121.6pt; padding: .75pt" height="21">
<p align="left">Dittmann J.</font></p>
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Experiments
</td>
with the effects of Ubichinon-Injeel and strong Ubichinon-Injeel on an
<td width="84" height="8"><i><font face="Optima-Oblique" size="1">
acellular system</span></b></p>
<p align="left">BM, </font></i><b><font face="Optima-Bold" size="1">1998</font></b><font face="Optima" size="1">,
2;</p>
</td>
<td width="121" style="width: 91.05pt; padding: .75pt" height="21"><span style="font-size: 7.5pt; font-family: Optima">Harisch G.,<br>
<p align="left">55-62.</font></p>
</td>
Dittmann J.</span></td>
<td width="92" height="8"><font face="Optima" size="1">
<td width="111" style="width: 83.0pt; padding: .75pt" height="21">
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">BM, </span></i><b><span style="font-size:7.5pt;font-family:Optima-Bold">1997</span></b><span style="font-size:7.5pt;font-family:Optima">,
<p align="left">Effects of dilutions</p>
<p align="left">and potencies of</p>
3;<o:p>
<p align="left">cAMP on some</p>
</o:p>
<p align="left">enzymatic activities</font></p>
</span></p>
<p><span style="font-size:7.5pt;font-family:Optima">99-104.</span></p>
</td>
</td>
<td width="203" height="8"><i><font face="Optima-Oblique" size="1">
<td width="90" style="width: 67.45pt; padding: .75pt" height="21">
<p align="left">In vitro </font></i><font face="Optima" size="1">study;</p>
<p><span style="font-size:7.5pt;font-family:Optima">Different effects of
<p align="left">basic research</font></p>
associations of various potencies and individual potencies</span></p>
</td>
</tr>
</td>
<td width="84" style="width: 62.9pt; padding: .75pt" height="21">
<tr>
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">In vitro </span></i><span style="font-size:7.5pt;font-family:Optima">study;<o:p>
<td width="171" height="8"><b><font face="Optima-Bold" size="1">
</o:p>
<p align="left">Studies of the principles of</p>
<p align="left">homeopathy; the changeover</p>
</span></p>
<p style="mso-line-height-alt:6.0pt"><span style="font-size:7.5pt;font-family:
<p align="left">from </font><i><font face="Optima-BoldOblique" size="1">in
Optima">basic research</span></p>
vivo </font></i><font face="Optima-Bold" size="1">to </font><i><font face="Optima-BoldOblique" size="1">in
vitro</p>
</td>
</tr>
</font></i><font face="Optima-Bold" size="1">
<tr style="height:6.0pt">
<p align="left">experimental research</font></b></p>
<td width="162" style="width: 121.6pt; padding: .75pt" height="15">
</td>
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Efficacy of
<td width="128" height="8"><font face="Optima" size="1">
the homeopathic drugs Suis and Arnica comp.-Heel® on lymphocyte and
<p align="left">Harisch G.,</p>
<p align="left">Dittmann J.</font></p>
phagocyte activity</span></b></p>
</td>
</td>
<td width="84" height="8"><i><font face="Optima-Oblique" size="1">
<td width="121" style="width: 91.05pt; padding: .75pt" height="15">
<p align="left">BM, </font></i><b><font face="Optima-Bold" size="1">1998</font></b><font face="Optima" size="1">,
<p class="MsoNormal"><span style="font-size:7.5pt;font-family:Optima">Enbergs
3;</p>
H.</span></p>
</td>
<p align="left">98-103.</font></p>
<td width="111" style="width: 83.0pt; padding: .75pt" height="15">
</td>
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">BM, </span></i><b><span style="font-size:7.5pt;font-family:Optima-Bold">1998</span></b><span style="font-size:7.5pt;font-family:Optima">,
<td width="92" height="8"><font face="Optima" size="1">
<p align="left">Potentised and</p>
1;<o:p>
<p align="left">non-potentised</p>
</o:p>
<p align="left">dilutions are</p>
</span></p>
<p align="left">equally effective,</p>
<p><span style="font-size:7.5pt;font-family:Optima">3-11.</span></p>
</td>
<p align="left">but have different</p>
<td width="90" style="width: 67.45pt; padding: .75pt" height="15">
<p align="left">actions</font></p>
<p style="mso-line-height-alt:6.0pt"><span style="font-size:7.5pt;font-family:
</td>
Optima">Effect of organotherapeutics and Arnica comp. -Heel® on immune system
<td width="203" height="8">
cells</span></p>
<p align="left"><font face="Optima-Oblique" size="1">B</font><font face="Optima" size="1">asic
research</font></p>
</td>
<td width="84" style="width: 62.9pt; padding: .75pt" height="15">
</td>
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">In vitro </span></i><span style="font-size:7.5pt;font-family:Optima">study;<o:p>
</tr>
<tr>
</o:p>
</span></p>
<td width="171" height="8"><font face="Optima-Bold" size="1"><b>
<p style="mso-line-height-alt:6.0pt"><span style="font-size:7.5pt;font-family:
<p align="left">Determination of the activity of</b></font> <b><font face="Optima-Bold" size="1">acid
Optima">basic research</span></p>
phosphatase with cAMP at</font></b> <b><font face="Optima-Bold" size="1">various
potencies</font></b></p>
</td>
</td>
</tr>
<td width="128" height="8"><font face="Optima" size="1">
<tr style="height:6.0pt">
<td width="162" style="width: 121.6pt; padding: .75pt" height="14">
<p align="left">Harisch G.,</p>
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Influence of
<p align="left">Dittmann J.</font></p>
dilutions and potencies of cAMP on different enzymatic systems</span></b></p>
</td>
</td>
<td width="84" height="8"><i><font face="Optima-Oblique" size="1">BM, </font></i><b><font face="Optima-Bold" size="1">1999</font></b><font face="Optima" size="1">,
<td width="121" style="width: 91.05pt; padding: .75pt" height="14"><span style="font-size: 7.5pt; font-family: Optima">Harisch G.,<br>
1; 4-8.</font></td>
Dittmann J.</span></td>
<td width="92" height="8"><font face="Optima" size="1">
<td width="111" style="width: 83.0pt; padding: .75pt" height="14">
<p align="left">Different effects on</font> <font face="Optima" size="1">enzymatic
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">BM, </span></i><b><span style="font-size:7.5pt;font-family:Optima-Bold">1998</span></b><span style="font-size:7.5pt;font-family:Optima">,
activity</font></p>
</td>
2;<o:p>
</o:p>
<td width="203" height="8"><i><font face="Optima-Oblique" size="1">
</span></p>
<p align="left">In vitro </font></i><font face="Optima" size="1">study;</p>
<p align="left">basic research</font></p>
<p><span style="font-size:7.5pt;font-family:Optima">55-62.</span></p>
</td>
</td>
<td width="90" style="width: 67.45pt; padding: .75pt" height="14">
</tr>
<p style="mso-line-height-alt:6.0pt"><span style="font-size:7.5pt;font-family:
<tr>
Optima">Effects of dilutions and potencies of cAMP on some enzymatic
<td width="171" height="8"><b><font face="Optima-Bold" size="1">
activities</span></p>
<p align="left">Contribution to study of the</p>
</td>
<p align="left">efficacy of homeopathic potencies</p>
<td width="84" style="width: 62.9pt; padding: .75pt" height="14">
<p align="left">of phosphorus</font></b></p>
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">In vitro </span></i><span style="font-size:7.5pt;font-family:Optima">study;<o:p>
</td>
</o:p>
<td width="128" height="8"><font face="Optima" size="1">Gomez J.C.</font></td>
</span></p>
<td width="84" height="8"><i><font face="Optima-Oblique" size="1">
<p style="mso-line-height-alt:6.0pt"><span style="font-size:7.5pt;font-family:
<p align="left">BT, </font></i><b><font face="Optima-Bold" size="1">1999</font></b><font face="Optima" size="1">,
Optima">basic research</span></p>
2;</p>
</td>
<p align="left">53-57.</font></p>
</td>
</tr>
<td width="92" height="8"><font face="Optima" size="1">
<tr style="height:6.0pt">
<td width="162" style="width: 121.6pt; padding: .75pt" height="1">
<p align="left">Effect of different</p>
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Studies of the
<p align="left">potencies of</p>
principles of homeopathy; the changeover from </span><i><span style="font-size:7.5pt;font-family:Optima-BoldOblique">in
<p align="left">phosphorus</font></p>
vivo </span></i><span style="font-size:7.5pt;font-family:Optima-Bold">to </span><i><span style="font-size:7.5pt;font-family:Optima-BoldOblique">in
</td>
vitro </span></i><span style="font-size:7.5pt;font-family:Optima-Bold">experimental
<td width="203" height="8"><font face="Optima" size="1">
<p align="left">Tests on guinea</p>
research</span></b></p>
</td>
<p align="left">pigs</font></p>
<td width="121" style="width: 91.05pt; padding: .75pt" height="1"><span style="font-size: 7.5pt; font-family: Optima">Harisch G.,<br>
</td>
</tr>
Dittmann J.</span></td>
<td width="111" style="width: 83.0pt; padding: .75pt" height="1">
<tr>
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">BM, </span></i><b><span style="font-size:7.5pt;font-family:Optima-Bold">1998</span></b><span style="font-size:7.5pt;font-family:Optima">,
<td width="171" height="8"><b><font face="Optima-Bold" size="1">
3;<o:p>
<p align="left">Determination of the activity of</p>
</o:p>
<p align="left">acid phosphatase in the presence</p>
<p align="left">of Ubichinon comp.</font></b></p>
</span></p>
<p><span style="font-size:7.5pt;font-family:Optima">98-103.</span></p>
</td>
</td>
<td width="128" height="8"><font face="Optima" size="1">
<td width="90" style="width: 67.45pt; padding: .75pt" height="1">
<p align="left">Harisch G.,</p>
<p align="left">Dittmann J.</font></p>
<p style="mso-line-height-alt:6.0pt"><span style="font-size:7.5pt;font-family:
Optima">Potentised and non-potentised dilutions are equally effective, but
</td>
have different actions</span></p>
<td width="84" height="8"><i><font face="Optima-Oblique" size="1">
</td>
<p align="left">BM, </font></i><b><font face="Optima-Bold" size="1">1999</font></b><font face="Optima" size="1">,
<td width="84" style="width: 62.9pt; padding: .75pt" height="1">
4;</p>
<p align="left">188-194.</font></p>
<p style="mso-line-height-alt:6.0pt"><span style="font-size:7.5pt;font-family:
Optima-Oblique">B</span><span style="font-size:7.5pt;font-family:Optima">asic
</td>
research</span></p>
<td width="92" height="8"><font face="Optima" size="1">
</td>
<p align="left">Effect of enzymatic</p>
</tr>
<p align="left">activity of</p>
<tr style="height:6.0pt">
<p align="left">homeopathic</p>
<td width="162" style="width: 121.6pt; padding: .75pt" height="17">
<p align="left">medicine</font></p>
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Determination
</td>
of the activity of</span></b> <b><span style="font-size:7.5pt;font-family:Optima-Bold">acid
<td width="203" height="8"><font face="Optima-Oblique" size="1">B</font><font face="Optima" size="1">asic
phosphatase with cAMP at</span></b> <b><span style="font-size:7.5pt;
research</font></td>
font-family:Optima-Bold">various potencies</span></b></p>
</tr>
<tr>
</td>
<td width="171" height="8"><b><font face="Optima-Bold" size="1">
<td width="121" style="width: 91.05pt; padding: .75pt" height="17"><span style="font-size: 7.5pt; font-family: Optima">Harisch G.,<br>
Dittmann J.</span></td>
<p align="left">Biochemical efficacy of</p>
<td width="111" style="width: 83.0pt; padding: .75pt" height="17">
<p align="left">homeopathic and electronic</p>
<p class="MsoNormal"><i><span style="font-size:7.5pt;font-family:Optima-Oblique">BM,
<p align="left">preparations of D8 potassium</p>
</span></i><b><span style="font-size:7.5pt;font-family:Optima-Bold">1999</span></b><span style="font-size:7.5pt;font-family:Optima">,
<p align="left">cyanate</font></b></p>
</td>
1; 4-8.</span></p>
</td>
<td width="128" height="8"><font face="Optima" size="1">
<td width="90" style="width: 67.45pt; padding: .75pt" height="17">
<p align="left">Dittmann J.,</p>
<p style="mso-line-height-alt:6.0pt"><span style="font-size:7.5pt;font-family:
<p align="left">Kanapin H.,</p>
Optima">Different effects on</span> <span style="font-size:7.5pt;font-family:
<p align="left">Harisch G.</font></p>
Optima">enzymatic activity</span></p>
</td>
</td>
<td width="84" height="8"><i><font face="Optima-Oblique" size="1">
<td width="84" style="width: 62.9pt; padding: .75pt" height="17">
<p align="left">FKM, </font></i><b><font face="Optima-Bold" size="1">1999</font></b><font face="Optima" size="1">,
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">In vitro </span></i><span style="font-size: 7.5pt; font-family: Optima">study;<br>
6;</p>
<p align="left">15-18.</font></p>
basic research</span></p>
</td>
</td>
</tr>
<td width="92" height="8"><font face="Optima" size="1">
<tr style="height:6.0pt">
<p align="left">Homeopathic</p>
<td width="162" style="width: 121.6pt; padding: .75pt" height="18">
<p align="left">potentisation is</p>
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Contribution
<p align="left">more effective than</p>
to study of the efficacy of homeopathic potencies of phosphorus</span></b></p>
<p align="left">electronic</p>
</td>
<p align="left">potentisation</font></p>
<td width="121" style="width: 91.05pt; padding: .75pt" height="18">
</td>
<td width="203" height="8"><font face="Optima-Oblique" size="1">B</font><font face="Optima" size="1">asic
<p class="MsoNormal"><span style="font-size:7.5pt;font-family:Optima">Gomez
research</font></td>
J.C.</span></p>
</tr>
</td>
<td width="111" style="width: 83.0pt; padding: .75pt" height="18">
<tr>
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">BT, </span></i><b><span style="font-size:7.5pt;font-family:Optima-Bold">1999</span></b><span style="font-size:7.5pt;font-family:Optima">,
<td width="171" height="8"><b><font face="Optima-Bold" size="1">
2; 53-57.</span></p>
<p align="left">Osteoporosis in vitro in rat tibiaderived</p>
</td>
<p align="left">osteoblasts is promoted</p>
<td width="90" style="width: 67.45pt; padding: .75pt" height="18">
<p align="left">by the homeopathic preparation,</p>
<p style="mso-line-height-alt:6.0pt"><span style="font-size:7.5pt;font-family:
<p align="left">FMS Calciumfluor</font></b></td>
Optima">Effect of different potencies of phosphorus</span></p>
<td width="128" height="8"><font face="Optima" size="1">
</td>
<p align="left">Palermo C.,</p>
<td width="84" style="width: 62.9pt; padding: .75pt" height="18">
<p align="left">Filanti C.,</p>
<p><span style="font-size:7.5pt;font-family:Optima">Tests on guinea</span><span style="font-size:7.5pt;font-family:
<p align="left">Poggi S.,</p>
<p align="left">Manduca P.</font></td>
Optima"> pigs</span></p>
</td>
<td width="84" height="8"><i><font face="Optima-Oblique" size="1">
</tr>
<p align="left">Cell Biol Int</font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">1999</font></b><font face="Optima" size="1">,</p>
<tr style="height:6.0pt">
<p align="left">23(1): 31-40.</font></td>
<td width="92" height="8"><b><font face="Optima-Bold" size="1">
<td width="162" style="width: 121.6pt; padding: .75pt" height="25">
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Determination
<p align="left">Stimulant</font></b></td>
of the activity of acid phosphatase in the presence of Ubichinon comp.</span></b></p>
<td width="203" height="8"><font face="Optima" size="1">
</td>
<p align="left">Osteogenesis</p>
<td width="121" style="width: 91.05pt; padding: .75pt" height="25"><span style="font-size: 7.5pt; font-family: Optima">Harisch G.,<br>
<p align="left">(trial with</p>
<p align="left">compound drug)</font></td>
Dittmann J.</span></td>
<td width="111" style="width: 83.0pt; padding: .75pt" height="25">
</tr>
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">BM, </span></i><b><span style="font-size:7.5pt;font-family:Optima-Bold">1999</span></b><span style="font-size:7.5pt;font-family:Optima">,
<tr>
4; 188-194.</span></p>
<td width="171" height="32" rowspan="2"><b><font face="Optima-Bold" size="1">
</td>
<p align="left">Thin-layer chromatography (TLC)</p>
<td width="90" style="width: 67.45pt; padding: .75pt" height="25">
<p align="left">of homeopathic active</p>
<p style="mso-line-height-alt:6.0pt"><span style="font-size:7.5pt;font-family:
<p align="left">constituents</font></b></td>
Optima">Effect of enzymatic activity of homeopathic medicine</span></p>
<td width="128" height="32" rowspan="2"><font face="Optima" size="1">Schmolz
M.</font></td>
</td>
<td width="84" height="32" rowspan="2"><i><font face="Optima-Oblique" size="1">
<td width="84" style="width: 62.9pt; padding: .75pt" height="25">
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><span style="font-size:
<p align="left">BM, </font></i><b><font face="Optima-Bold" size="1">1999</font></b><font face="Optima" size="1">,
7.5pt;font-family:Optima-Oblique">B</span><span style="font-size:7.5pt;
5;</p>
<p align="left">248-250.</font></td>
font-family:Optima">asic research</span></p>
</td>
<td width="92" height="16"><font face="Optima" size="1">
</tr>
<p align="left">Constituents of</font> <font face="Optima" size="1">Arnica
<tr style="height:6.0pt">
comp.-</font> <font face="Optima" size="1">Heel® ointment:</font> <font face="Optima" size="1">electrophoresis</font>
<font face="Optima" size="1">accelerates their</font> <font face="Optima" size="1">skin
<td width="162" style="width: 121.6pt; padding: .75pt" height="21">
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Biochemical
penetration.</font> </td>
efficacy of homeopathic and electronic preparations of D8 potassiumcyanate</span></b></p>
<td width="203" height="32"><font face="Optima" size="1">Basic research</font></td>
</tr>
</td>
<td width="121" style="width: 91.05pt; padding: .75pt" height="21"><span style="font-size: 7.5pt; font-family: Optima">Dittmann J.,<br>
<tr>
Kanapin H.,<br>
<td width="92" height="16"><font face="Optima" size="1">Effect of</font> <font face="Optima" size="1">homeopathic</font>
Harisch G.</span></td>
<font face="Optima" size="1">constituents on</font> <font face="Optima" size="1">enzymatic
<td width="111" style="width: 83.0pt; padding: .75pt" height="21">
activity.</font></td>
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">FKM, </span></i><b><span style="font-size:7.5pt;font-family:Optima-Bold">1999</span></b><span style="font-size:7.5pt;font-family:Optima">,
<td width="203" height="4"><font face="Optima" size="1">Basic research</font></td>
</tr>
6; 15-18.</span></p>
<tr>
</td>
<td width="171" height="8"><b><font face="Optima-Bold" size="1">
<td width="90" style="width: 67.45pt; padding: .75pt" height="21">
<p style="mso-line-height-alt:6.0pt"><span style="font-size:7.5pt;font-family:
<p align="left">Efficacy of a potentised</p>
Optima">Homeopathic potentisation is more effective than electronic
<p align="left">homeopathic drug in reducing</p>
potentisation</span></p>
<p align="left">cytotoxic effects produced by</p>
</td>
<p align="left">arsenic trioxide in mice</font></b></td>
<td width="128" height="8"><font face="Optima" size="1">
<td width="84" style="width: 62.9pt; padding: .75pt" height="21">
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><span style="font-size:
<p align="left">Datta S.,</p>
7.5pt;font-family:Optima-Oblique">B</span><span style="font-size:7.5pt;
<p align="left">Mallick P.,</p>
<p align="left">Bukhsh A.R.</font></td>
font-family:Optima">asic research</span></p>
</td>
<td width="84" height="8"><i><font face="Optima-Oblique" size="1">
</tr>
<p align="left">Complement Ther</p>
<tr style="height:6.0pt">
<p align="left">Med</font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">1999
<td width="162" style="width: 121.6pt; padding: .75pt" height="11">
</font></b><font face="Optima" size="1">Jan;</p>
<p align="left">7 (8): 62-75 </font><b><font face="Optima-Bold" size="1">(a).</font></b></td>
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Osteoporosis
in vitro in rat tibia derived osteoblasts is promoted by the homeopathic
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Protective</font></b></td>
preparation, FMS Calciumfluor</span></b></p>
<td width="203" height="8"><font face="Optima" size="1">
</td>
<p align="left">Arsenic trioxide</p>
<td width="121" style="width: 91.05pt; padding: .75pt" height="11"><span style="font-size: 7.5pt; font-family: Optima">Palermo C.,<br>
<p align="left">toxicity</font></td>
</tr>
Filanti C.,<br>
<tr>
Poggi S.,<br>
Manduca P.</span></td>
<td width="171" height="8"><b><font face="Optima-Bold" size="1">
<td width="111" style="width: 83.0pt; padding: .75pt" height="11">
<p align="left">Efficacy of a potentised</p>
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Cell Biol
<p align="left">homeopathic drug in reducing</p>
Int</span></i><span style="font-size:7.5pt;font-family:Optima">, </span><b><span style="font-size:7.5pt;font-family:Optima-Bold">1999</span></b><span style="font-size:7.5pt;font-family:Optima">,<o:p>
<p align="left">cytotoxic effects produced by</p>
</o:p>
<p align="left">arsenic trioxide in mice</font></b></td>
</span></p>
<td width="128" height="8"><font face="Optima" size="1">
<p align="left">Datta S.,</p>
<p><span style="font-size:7.5pt;font-family:Optima">23(1): 31-40.</span></p>
</td>
<p align="left">Mallick P.,</p>
<td width="90" style="width: 67.45pt; padding: .75pt" height="11">
<p align="left">Bukhsh A.R.</font></td>
<td width="84" height="8"><i><font face="Optima-Oblique" size="1">
<p style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;
font-family:Optima-Bold">Stimulant</span></b></p>
<p align="left">Complement Ther</p>
</td>
<p align="left">Med</font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">1999
<td width="84" style="width: 62.9pt; padding: .75pt" height="11"><span style="font-size: 7.5pt; font-family: Optima">Osteogenesis<br>
</font></b><font face="Optima" size="1">Sep;</p>
(trial with<br>
<p align="left">7 (3): 156-63 </font><b><font face="Optima-Bold" size="1">(b).</font></b></td>
compound drug)</span></td>
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Protective</font></b></td>
</tr>
<td width="203" height="8"><font face="Optima" size="1">
<tr style="height:24.0pt">
<p align="left">Arsenic trioxide</p>
<td width="162" rowspan="2" style="width: 121.6pt; padding: .75pt" height="34">
<p align="left">toxicity</font></td>
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Thin-layer
</tr>
chromatography (TLC) of homeopathic active constituents</span></b></p>
<tr>
</td>
<td width="171" height="8"><font face="Optima-Bold" size="1"><b>
<td width="121" rowspan="2" style="width: 91.05pt; padding: .75pt" height="34">
<p align="left">Non-cytotoxic antiviral action of</b></font> <font face="Optima-Bold" size="1"><b>a
<p class="MsoNormal"><span style="font-size:7.5pt;font-family:Optima">Schmolz
homeopathic drug</b></font></td>
M.</span></p>
<td width="128" height="8"><font face="Optima" size="1">Heine H.</font></td>
</td>
<td width="84" height="8"><i><font face="Optima-Oblique" size="1">
<td width="111" rowspan="2" style="width: 83.0pt; padding: .75pt" height="34">
<p align="left">Ärzteitschrift für</p>
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">BM, </span></i><b><span style="font-size:7.5pt;font-family:Optima-Bold">1999</span></b><span style="font-size:7.5pt;font-family:Optima">,
<p align="left">Neturheilverfahre</font></i><font face="Optima" size="1">,</p>
5;<o:p>
</font><b><font face="Optima-Bold" size="1">
</o:p>
<p align="left">2000</font></b><font face="Optima" size="1">; 41: 542-7.</font></td>
</span></p>
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Stimulant</font></b></td>
<p><span style="font-size:7.5pt;font-family:Optima">248-250.</span></p>
<td width="203" height="8"><font face="Symbol" size="1">
</td>
<p align="left">ã </font><font face="Optima" size="1">interferon</p>
<td width="90" style="width: 67.45pt; padding: .75pt" height="67">
<p align="left">synthesis</font></td>
<p><span style="font-size:7.5pt;font-family:Optima">Constituents of</span>
</tr>
<span style="font-size:7.5pt;font-family:Optima">Arnica comp.-</span> <span style="font-size:7.5pt;font-family:Optima">Heel®
<tr>
ointment:</span> <span style="font-size:7.5pt;font-family:Optima">electrophoresis</span>
<td width="171" height="8"><b><font face="Optima-Bold" size="1">
<span style="font-size:7.5pt;font-family:Optima">accelerates their</span> <span style="font-size:7.5pt;font-family:Optima">skin
<p align="left">Efficacy of a potentised</p>
penetration.</span></p>
<p align="left">homeopathic drug in reducing</p>
</td>
<p align="left">cytotoxic effects produced by</p>
<td width="84" style="width: 62.9pt; padding: .75pt" height="67">
<p align="left">arsenic trioxide in mice</font></b></td>
<td width="128" height="8"><font face="Optima" size="1">
<p class="MsoNormal"><span style="font-size:7.5pt;font-family:Optima">Basic
<p align="left">Kundu S.N.,</p>
research</span></p>
</td>
<p align="left">Mitra K.,</p>
</tr>
<p align="left">Khuda</p>
<tr style="height:3.0pt">
<p align="left">Bukhsh A.R.</font></td>
<td width="84" height="8"><i><font face="Optima-Oblique" size="1">
<td width="90" style="width: 67.45pt; padding: .75pt" height="1">
<p class="MsoNormal"><span style="font-size:7.5pt;font-family:Optima">Effect
<p align="left">Complement Ther</p>
<p align="left">Med </font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">2000
of</span> <span style="font-size:7.5pt;font-family:Optima">homeopathic</span>
<span style="font-size:7.5pt;font-family:Optima">constituents on</span> <span style="font-size:7.5pt;font-family:Optima">enzymatic
</font></b><font face="Optima" size="1">Sep;</p>
<p align="left">1 (3): 157-65.</font></td>
activity.</span></p>
</td>
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Protective</font></b></td>
<td width="203" height="8"><font face="Optima" size="1">
<td width="84" style="width: 62.9pt; padding: .75pt" height="1">
<p class="MsoNormal" style="mso-line-height-alt:3.0pt"><span style="font-size:
<p align="left">Arsenic trioxide</p>
7.5pt;font-family:Optima">Basic research</span></p>
<p align="left">toxicity</font></td>
</tr>
</td>
<tr>
</tr>
<tr style="height:6.0pt">
<td width="171" height="8"><b><font face="Optima-Bold" size="1">
<td width="162" style="width: 121.6pt; padding: .75pt" height="35">
<p align="left">Stimulatory effect of some plant</p>
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Efficacy of a
<p align="left">extracts used in homeopathy on</p>
potentised homeopathic drug in reducing cytotoxic effects produced by
<p align="left">the phagocytosis induced</p>
<p align="left">chemiluminescence of</p>
arsenic trioxide in mice</span></b></p>
</td>
<p align="left">polymorphonuclear leukocytes</font></b></td>
<td width="128" height="8"><font face="Optima" size="1">
<td width="121" style="width: 91.05pt; padding: .75pt" height="35"><span style="font-size: 7.5pt; font-family: Optima">Datta S.,<br>
<p align="left">Crocnan D.,</p>
Mallick P.,<br>
<p align="left">Greabu M.,</p>
Khuda Bukhsh A.R.</span></td>
<td width="111" style="width: 83.0pt; padding: .75pt" height="35">
<p align="left">Olinescu R.</font></td>
<td width="84" height="8"><i><font face="Optima-Oblique" size="1">
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Complement Ther<br>
Med</span></i><span style="font-size:7.5pt;font-family:Optima">, </span><b><span style="font-size:7.5pt;font-family:Optima-Bold">1999</span></b><span style="font-size:7.5pt;font-family:Optima">Jan;<br>
<p align="left">Rocz Akad Med</p>
<p align="left">Biochemist</font></i><font face="Optima" size="1">, </font><b><font face="Optima-Bold" size="1">2000</font></b><font face="Optima" size="1">;</p>
7 (8): 62-75 </span><b><span style="font-size:7.5pt;font-family:Optima-Bold">(a).</span></b></p>
</td>
<p align="left">45: 246-254.</font></td>
<td width="92" height="8"><b><font face="Optima-Bold" size="1">Stimulant</font></b></td>
<td width="90" style="width: 67.45pt; padding: .75pt" height="35">
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Protective</span></b></p>
<td width="203" height="8"><font face="Optima" size="1">
</td>
<p align="left">Phagocytosis</font></td>
<td width="84" style="width: 62.9pt; padding: .75pt" height="35"><span style="font-size: 7.5pt; font-family: Optima">Arsenic trioxide<br>
</tr>
<tr>
toxicity</span></td>
</tr>
<td width="171" height="8"><b><font face="Optima-Bold" size="1">
<tr style="height:6.0pt">
<p align="left">Difference between the efficacy</p>
<td width="162" style="width: 121.6pt; padding: .75pt" height="32">
<p align="left">of single potencies and chords</font></b></td>
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Efficacy of a
<td width="128" height="8"><font face="Optima" size="1">
potentised homeopathic drug in reducing cytotoxic effects produced by
<p align="left">Dittmann J.,</p>
<p align="left">Harisch G.</font></td>
arsenic trioxide in mice</span></b></p>
</td>
<td width="84" height="8"><i><font face="Optima-Oblique" size="1">
<p align="left">BM, </font></i><b><font face="Optima-Bold" size="1">2000</font></b><font face="Optima" size="1">,
<td width="121" style="width: 91.05pt; padding: .75pt" height="32"><span style="font-size: 7.5pt; font-family: Optima">Datta S.,<br>
1;</p>
Mallick P.,<br>
<p align="left">18-23.</font></td>
Khuda Bukhsh A.R.</span></td>
<td width="92" height="8"><font face="Optima" size="1">
<td width="111" style="width: 83.0pt; padding: .75pt" height="32">
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Complement
<p align="left">Potency chords are</p>
Ther<br>
<p align="left">more effective than</p>
Med</span></i><span style="font-size:7.5pt;font-family:Optima">, </span><b><span style="font-size:7.5pt;font-family:Optima-Bold">1999
<p align="left">single potencies</font></td>
</span></b><span style="font-size:7.5pt;font-family:Optima">Sep;<br>
<td width="203" height="8"><font face="Optima" size="1">Basic research</font></td>
7 (3): 156-63 </span><b><span style="font-size:7.5pt;font-family:Optima-Bold">(b).</span></b></p>
</tr>
<tr>
</td>
<td width="171" height="28"><b><font face="Optima-Bold" size="1">
<td width="90" style="width: 67.45pt; padding: .75pt" height="32">
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Protective</span></b></p>
<p align="left">Influence of some homeopathic</p>
</td>
<p align="left">drugs on the catalytic activity of</p>
<td width="84" style="width: 62.9pt; padding: .75pt" height="32"><span style="font-size: 7.5pt; font-family: Optima">Arsenic trioxide<br>
<p align="left">uricase, acid phosphatase and the</p>
toxicity</span></td>
<p align="left">cytosol glutathion-S-transferase</font></b></td>
</tr>
<td width="128" height="28"><font face="Optima" size="1">
<tr style="height:6.0pt">
<p align="left">Dittmann J.,</p>
<td width="162" style="width: 121.6pt; padding: .75pt" height="17">
<p align="left">Kanapin H.,</p>
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Non-cytotoxic
<p align="left">Harisch G.</font></td>
<td width="84" height="28"><i><font face="Optima-Oblique" size="1">
antiviral action of</span></b> <b><span style="font-size:7.5pt;font-family:
Optima-Bold">a homeopathic drug</span></b></p>
<p align="left">BM, </font></i><b><font face="Optima-Bold" size="1">2000</font></b><font face="Optima" size="1">,
3;</p>
</td>
<td width="121" style="width: 91.05pt; padding: .75pt" height="17">
<p align="left">125-131</font></td>
<td width="92" height="28"><font face="Optima" size="1">
<p class="MsoNormal"><span style="font-size:7.5pt;font-family:Optima">Heine
<p align="left">Effect of D8</p>
H.</span></p>
</td>
<p align="left">potencies on three</p>
<td width="111" style="width: 83.0pt; padding: .75pt" height="17">
<p align="left">different enzymatic</p>
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Ärzteitschrift
<p align="left">systems</font></td>
fü</span></i><i><span style="font-size:7.5pt;font-family:Optima-Oblique">rNeturheilverfahre,
<td width="203" height="28"><font face="Optima" size="1">Basic research</font></td>
</span></i><b><span style="font-size:7.5pt;font-family:Optima-Bold">2000</span></b><span style="font-size:7.5pt;font-family:Optima">;
</tr>
<tr>
41: 542-7.</span></p>
</td>
<td width="171" height="37"><b><font face="Optima-Bold" size="1">
<td width="90" style="width: 67.45pt; padding: .75pt" height="17">
<p align="left">Influence of some homeopathic</p>
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Stimulant</span></b></p>
<p align="left">drugs on the catalytic activity of</p>
</td>
<p align="left">cAMP-dependent protein kinases</font></b></td>
<td width="128" height="37"><font face="Optima" size="1">
<td width="84" style="width: 62.9pt; padding: .75pt" height="17">
<p><span style="font-size:7.5pt;font-family:Symbol">ã </span><span style="font-size:7.5pt;font-family:Optima">interferon<o:p>
<p align="left">Dittmann J.,</p>
<p align="left">Kanapin H.,</p>
</o:p>
<p align="left">Harisch G.</font></td>
</span></p>
<td width="84" height="37"><i><font face="Optima-Oblique" size="1">
<p style="mso-line-height-alt:6.0pt"><span style="font-size:7.5pt;font-family:
Optima">synthesis</span></p>
<p align="left">BM, </font></i><b><font face="Optima-Bold" size="1">2000</font></b><font face="Optima" size="1">,
6;</p>
</td>
</tr>
<p align="left">289-296.</font></td>
<td width="92" height="37"><font face="Optima" size="1">
<tr style="height:6.0pt">
<td width="162" style="width: 121.6pt; padding: .75pt" height="42">
<p align="left">Effect of different</p>
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Efficacy of a
<p align="left">potencies of 5</p>
potentised homeopathic drug in reducing cytotoxic effects produced by
<p align="left">substances on</p>
<p align="left">enzymatic activity</font></td>
arsenic trioxide in mice</span></b></p>
</td>
<td width="203" height="37"><font face="Optima" size="1">Basic research</font></td>
<td width="121" style="width: 91.05pt; padding: .75pt" height="42"><span style="font-size: 7.5pt; font-family: Optima">Kundu S.N.,<br>
</tr>
<tr>
Mitra K.,<br>
Khuda Bukhsh A.R.</span></td>
<td width="171" height="38"><b><font face="Optima-Bold" size="1">
<td width="111" style="width: 83.0pt; padding: .75pt" height="42">
<p align="left">Neuroprotection from glutamate</p>
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Complement
<p align="left">toxicity with ultra-low dose</p>
Ther<br>
<p align="left">glutamate</font></b></td>
Med </span></i><span style="font-size:7.5pt;font-family:Optima">, </span><b><span style="font-size:7.5pt;font-family:Optima-Bold">2000
<td width="128" height="38">
<p align="left"><font face="Optima" size="1">Jonas W.,</p>
</span></b><span style="font-size:7.5pt;font-family:Optima">Sep;<br>
<p align="left">Lin Y.,</p>
1 (3): 157-65.</span></p>
</td>
<p align="left">Zortella F.</font></td>
<td width="84" height="38"><i><font face="Optima-Oblique" size="1">
<td width="90" style="width: 67.45pt; padding: .75pt" height="42">
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Protective</span></b></p>
<p align="left">Neuroreport</font></i><font face="Optima" size="1">,</p>
</td>
</font><b><font face="Optima-Bold" size="1">
<td width="84" style="width: 62.9pt; padding: .75pt" height="42"><span style="font-size: 7.5pt; font-family: Optima">Arsenic trioxide<br>
<p align="left">2001 </font></b><font face="Optima" size="1">Feb 92; 12</p>
<p align="left">(2): 335-9.</font></td>
toxicity</span></td>
</tr>
<td width="92" height="38"><b><font face="Optima-Bold" size="1">Protective</font></b></td>
<tr style="height:6.0pt">
<td width="203" height="38"><font face="Optima" size="1">Glutamate
<td width="162" style="width: 121.6pt; padding: .75pt" height="32">
toxicity</font></td>
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Stimulatory
</tr>
effect of some plant extracts used in homeopathy on the phagocytosis
</table>
induced chemiluminescence of polymorphonuclear leukocytes</span></b></p>
</div>
</td>
<font face="Optima" size="1">
<td width="121" style="width: 91.05pt; padding: .75pt" height="32"><span style="font-size: 7.5pt; font-family: Optima">Crocnan D.,<br>
<p align="left">&nbsp;</p>
Greabu M.,<br>
<p align="left">KEY: BT = Biomedical Therapy</p>
Olinescu R.</span></td>
<p align="left">BM = Biologische Medizin</p>
<td width="111" style="width: 83.0pt; padding: .75pt" height="32">
<p align="left">FKM = Forschung Komplementär Medizin</p>
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Rocz Akad Med<br>
</font></font></font></font></font></font></font></font>[[User:Ramaanand|Ramaanand]] ([[User talk:Ramaanand|talk]]) 02:14, 17 March 2008 (UTC)Dr.Jhingadé
Biochemist</span></i><span style="font-size:7.5pt;font-family:Optima">, </span><b><span style="font-size:7.5pt;font-family:Optima-Bold">200</span></b><span style="font-size: 7.5pt"><b>0;</b><br>
45: 246-254.</span></p>
</td>
<td width="90" style="width: 67.45pt; padding: .75pt" height="32">
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Stimulant</span></b></p>
</td>
<td width="84" style="width: 62.9pt; padding: .75pt" height="32">
<p style="mso-line-height-alt:6.0pt"><span style="font-size:7.5pt;font-family:
Optima">Phagocytosis</span></p>
</td>
</tr>
<tr style="height:6.0pt">
<td width="162" style="width: 121.6pt; padding: .75pt" height="16">
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Difference
between the efficacy of single potencies and chords</span></b></p>
</td>
<td width="121" style="width: 91.05pt; padding: .75pt" height="16"><span style="font-size: 7.5pt; font-family: Optima">Dittmann J.,<br>
Harisch G.</span></td>
<td width="111" style="width: 83.0pt; padding: .75pt" height="16">
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">BM, </span></i><b><span style="font-size:7.5pt;font-family:Optima-Bold">2000</span></b><span style="font-size:7.5pt;font-family:Optima">,
1; 18-23.</span></p>
</td>
<td width="90" style="width: 67.45pt; padding: .75pt" height="16">
<p style="mso-line-height-alt:6.0pt"><span style="font-size:7.5pt;font-family:
Optima">Potency chords are more effective than single potencies</span></p>
</td>
<td width="84" style="width: 62.9pt; padding: .75pt" height="16">
<p class="MsoNormal" style="mso-line-height-alt:6.0pt"><span style="font-size:
7.5pt;font-family:Optima">Basic research</span></p>
</td>
</tr>
<tr style="height:21.0pt">
<td width="162" style="width: 121.6pt; padding: .75pt" height="1">
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Influence of
some homeopathic drugs on the catalytic activity of uricase, acid
phosphatase and the cytosol glutathion-S-transferase</span></b></p>
</td>
<td width="121" style="width: 91.05pt; padding: .75pt" height="1">
<p><span style="font-size: 7.5pt; font-family: Optima">Dittmann J.,<br>
Kanapin H.,<br>
Harisch G.</span></p>
</td>
<td width="111" style="width: 83.0pt; padding: .75pt" height="1">
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">BM, </span></i><b><span style="font-size:7.5pt;font-family:Optima-Bold">2000</span></b><span style="font-size:7.5pt;font-family:Optima">,
3;<o:p>
</o:p>
</span></p>
<p><span style="font-size:7.5pt;font-family:Optima">125-131</span></p>
</td>
<td width="90" style="width: 67.45pt; padding: .75pt" height="1">
<p><span style="font-size:7.5pt;font-family:Optima">Effect of D8 potencies
on three different enzymatic systems</span></p>
</td>
<td width="84" style="width: 62.9pt; padding: .75pt" height="1">
<p class="MsoNormal"><span style="font-size:7.5pt;font-family:Optima">Basic
research</span></p>
</td>
</tr>
<tr style="height:27.75pt">
<td width="162" style="width: 121.6pt; padding: .75pt" height="17">
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Influence of
some homeopathic drugs on the catalytic activity of cAMP-dependent protein
kinases</span></b></p>
</td>
<td width="121" style="width: 91.05pt; padding: .75pt" height="17"><span style="font-size: 7.5pt; font-family: Optima">Dittmann J.,<br>
Kanapin H.,<br>
Harisch G.</span></td>
<td width="111" style="width: 83.0pt; padding: .75pt" height="17">
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">BM, </span></i><b><span style="font-size:7.5pt;font-family:Optima-Bold">2000</span></b><span style="font-size:7.5pt;font-family:Optima">,
6;<o:p>
</o:p>
</span></p>
<p><span style="font-size:7.5pt;font-family:Optima">289-296.</span></p>
</td>
<td width="90" style="width: 67.45pt; padding: .75pt" height="17">
<p><span style="font-size:7.5pt;font-family:Optima">Effect of different
potencies of 5 substances on enzymatic activity</span></p>
</td>
<td width="84" style="width: 62.9pt; padding: .75pt" height="17">
<p class="MsoNormal"><span style="font-size:7.5pt;font-family:Optima">Basic
research</span></p>
</td>
</tr>
<tr style="height:28.5pt">
<td width="162" style="width: 121.6pt; padding: .75pt" height="1">
<p><b><span style="font-size:7.5pt;font-family:Optima-Bold">Neuroprotection
from glutamate toxicity with ultra-low dose glutamate</span></b></p>
</td>
<td width="121" style="width: 91.05pt; padding: .75pt" height="1"><span style="font-size: 7.5pt; font-family: Optima">Jonas W.,<br>
Lin Y.,<br>
Zortella F.</span></td>
<td width="111" style="width: 83.0pt; padding: .75pt" height="1">
<p><i><span style="font-size:7.5pt;font-family:Optima-Oblique">Neuroreport,<br>
</span></i><b><span style="font-size:7.5pt;font-family:Optima-Bold">2001 </span></b><span style="font-size:7.5pt;font-family:Optima">Feb
92; 1</span><span style="font-size: 7.5pt; font-family: Optima">2<br>
(2): 335-9.</span></p>
</td>
<td width="90" style="width: 67.45pt; padding: .75pt" height="1">
<p class="MsoNormal"><b><span style="font-size:7.5pt;font-family:Optima-Bold">Protective</span></b></p>
</td>
<td width="84" style="width: 62.9pt; padding: .75pt" height="1">
<p class="MsoNormal"><span style="font-size:7.5pt;font-family:Optima">Glutamate
toxicity</span></p>
</td>
</tr>
</table>
<p><b><span style="font-size:7.5pt;font-family:Optima">&nbsp;KEY: BT =
Biomedical Therapy</span></b></p>
<p><b><span style="font-size:7.5pt;font-family:Optima">BM = Biologische Medizin</span></b></p>
<p><b><span style="font-size:7.5pt;font-family:Optima">FKM = Forschung
Komplementär Medizin</span></b></p>


==wikified version of the table==
==wikified version of the table==

Revision as of 02:55, 23 March 2008

Dear Tim,
Please put this on the Talk:Homeopathy Page and mention it is posted by me (or else the others may think I've bribed you); I'm not yet able to post there directly myself because the Page is semi-writeprotected.

Here are some of the studies/clinical trials:-

STUDIES OF THE ACTIVITY OF HOMEOPATHIC MEDICINES

ORIGINAL/TRANSLATED TITLE

AUTHOR(S)

PUBLICATION

ACTIVITY

STUDY

Inhibition of lymphoblast
transformation test (LTT) in
phytohaemagglutinin (PHA) with
Phytolacca americana in
homeopathic dilution

Colas H.,
Aubin M.,
Picard P.,
Lebecq J.C.

Ann. Homéopat.<o:p> </o:p>

Fr., 1975, 6: 1-11.

Inhibitory

Lymphoblast<o:p> </o:p>

transformation

Inquiry into the limits of biological effects of chemical compounds in tissue culture. I. Low dose effects of mercuric chloride

Mansvelt J.D.,
van Amons E.

Z. Naturtorschung,<o:p> </o:p>
1975, 30:
643-649.

Inhibitory

Lymphocyte<o:p> </o:p>

growth

The effects of Belladonna and Ferrum phosphoricum on the chemoluminescence of human poly-morphonuclear neutrophils

Poitevin B.,
     Aubin M.,
Royer J.F.

Ann. Homéop. Fr.,<o:p> </o:p>

1983, 3: 5-12.

Inhibitory

Radical release

Effect of aconitum and veratrum on the isolated perfused heart of the common eel (Anguilla anguilla)

Pennec J.P.,
Aubin M.

Comp. Biochem.<o:p> </o:p>
Physiol.
, 1984,
776: 367-369.

Protective

Aconitine toxicity

Elements of homeopathic pharmacology

Aubin M.

Homéopathie Franç., 1984, 72:231- 235

Protective

Aconitine toxicity

The effect of homeopathic preparations on the phagocyte activity of granulocytes. In vitro tests and double-blind controlled trials

Wagner H.,
     Jurcic K.,
Doenicke A.,
Rosenhuber E.,
Behrens N.

Arzneim.
Forsch./Drug Res.,
1986, 36:
1424-1425.

Stimulant

Phagocytosis

Approach to quantitative analysis of the effect of Apis mellifica on the degranulation of human basophils cultivated in vitro

Poitevin B.,
     Aubin M.,
Benveniste J.

Innov. Tech. Biol.
Med.
, 1986, 7:
64-68.

Inhibitory

Basophil<o:p> </o:p>

degranulation

In vitro stimulation of human granulocytes and lymphocytes by pico- and femtogram quantities of cytostatic agents

Wagner H.,
     Kreher B.,
Jurcic K.

Arzneim. Forsch./Drug Res., 1988, 38: 273-275.

Stimulant

Lymphocyte<o:p> </o:p>

growth

Human basophil degranulation triggered by very dilute antiserum against IgE

Davenas E., Beauvais F., Amara J., Robinson M., Miadonna A., Tedeschi A., Pomeranz B., Fortner P., Belon P., Sainte-Laudy J., Poitevin B., Benveniste J.

Nature, 1988,<o:p> </o:p>

333: 816-818.

Stimulant

Basophils

In vitro immunological degranulation of human basophils is modulated by lung histamine and Apis mellifica

Poitevin B.,
     Davenas E.,
Benveniste J.

Brit. J. Clin.
Pharmacol.
, 1988,
25: 439-444.

Inhibitory

Basophil
degranulation

Cytotoxic agents as immunomodulators

Wagner H.,
Kreher B.

Proc. of the 3rd
GIRI meetin
g,
Paris,
1989, 31-
46.

Stimulant

Lymphocyte<o:p> </o:p>

growth

Contributions of fundamental research in homeopathy

Boiron J.,
Belon P.

Berl. J. Res. Hom.,
1990, 1: 34-35.

Inhibitory

Basophil
degranulation

Synergism of action between indoleacetic acid (IAA) and highlydiluted solutions of CaCO3 on the growth of oat coleoptiles

Bornoroni C.

Berl. J. Res. Hom.,
1991
, 1 (4/5): 275-278.

Stimulant

Growth of plant cells

Study of the action of Hahnemannian dilutions of mercury chloride on the mitotic index in animal cell cultures.

Boiron J.,
     Abecassis J.,
Cotte J.,
Bernard A.M.

Ann. Homéop.Fr., 1991, 23:<o:p> </o:p>

43-49.

Protective

Hg toxicity

Dual effects of formylpeptides on the adhesion of endotoxin-primed human neutrophils

Bellavite P.,
     Chirumbolo S.,
Lippi G.,
Andrioli G.,
Bonazzi L.,
Ferro I.

Cell. Biochem.
Funct.
, 1993, 11: 231-239.

Inhibitory

Cell adhesion
(bact. pept.
10-8-10-9)

Effects of homeopathic preparations of organic acids and of minerals on the oxidative metabolism of human neutrophils

Chirumbolo S.,
     Signorini A.,
Bianchi I.,
Lippi G.,
Bellavite P.

Br. Hom. J., 1993,<o:p> </o:p>

82: 227-244.

Inhibitory

Leucocyte
     activation
(metabolism)

Platelets/endothelial cells interactions in presence of acetylsalicylic acid at ultra low dose

Doutremepuich
     C.,
Lalanne M.C.,
Ramboer I.,
Sertillanges
M.N.,
De Seze O.

Omeomed 92 (C.
Bornoroni, ed.),

1993
, Editrice
Compositori,
Bologna:
109-115.

Inhibitory

Prostacyclin<o:p> </o:p>

release

Effect of high dilutions of epidermal growth factor (EGF) on in vitro proliferation of keratinocyte and fibroblast cell lines

Fougeray S.,
     Moubry K.,
Vallot N.,
Bastide M.

Br. Hom. J., 1993,<o:p> </o:p>

82: 124-125.

Inhibitory

Growth of<o:p> </o:p>

keratinocytes

Effects of different homeopathic potencies of Lachesis on lymphocyte cultures obtained from rabbit blood

Enbergs H.,
Arndt G.

Biol. Tier., 1993, 4.

Stimulant

Mitotic and
     immunostimulating
activity (bact. pept
10-5-10-6)

The effect of homeopathic potencies of housedust mite on the migration of house-dust sensitive human leukocytes

Gibson S.L.,
Gibson R.G.

Complement.
Ther. Med.
, 1996,
4: 169-171.

Stimulant

Leucocyte
chemotaxis

The effects of Nux vomica Homaccord and Atropinum comp. on intestinal activity in vitro

Kanui T.I.,
Enbergs H.

Biol. Tier., 1996/1, 43-47.

Stimulant

Contraction of
intestinal muscles

Application of flow cytometry to the analysis of the immunosuppressive effect of histamine dilutions on human basophil action: effect ofcimetidine

Sainte-Laudy J.,
Belon P.

Inflamm. Res.,
1997, 46:
S27-S28.

Inhibitory

Basophil
degranulation

Effects of Podophillum pellatum compounds in various preparations and dilutions on human neutrophil functions in vitro

Chirumbolo S.,
     Conforti A.,
Lussignoli S.,
Metelmann H.
et Al.

Br. Hom. J., 1997;<o:p> </o:p>

86-16.

Inhibitory

Release of<o:p> </o:p>

superoxides

In vivo and in vitro studies on the efficiency of potentized and nonpotentized substances

Harisch G.,
Dittmann J.

BT, 1997, 2;<o:p> </o:p>

40-46.

Difference between potentised and non-potentised substances

In vivo and in vitro study; basic research

Experiments with the effects of Ubichinon-Injeel and strong Ubichinon-Injeel on an acellular system

Harisch G.,
Dittmann J.

BM, 1997, 3;<o:p> </o:p>

99-104.

Different effects of associations of various potencies and individual potencies

In vitro study;<o:p> </o:p>

basic research

Efficacy of the homeopathic drugs Suis and Arnica comp.-Heel® on lymphocyte and phagocyte activity

Enbergs H.

BM, 1998, 1;<o:p> </o:p>

3-11.

Effect of organotherapeutics and Arnica comp. -Heel® on immune system cells

In vitro study;<o:p> </o:p>

basic research

Influence of dilutions and potencies of cAMP on different enzymatic systems

Harisch G.,
Dittmann J.

BM, 1998, 2;<o:p> </o:p>

55-62.

Effects of dilutions and potencies of cAMP on some enzymatic activities

In vitro study;<o:p> </o:p>

basic research

Studies of the principles of homeopathy; the changeover from in vivo to in vitro experimental research

Harisch G.,
Dittmann J.

BM, 1998, 3;<o:p> </o:p>

98-103.

Potentised and non-potentised dilutions are equally effective, but have different actions

Basic research

Determination of the activity of acid phosphatase with cAMP at various potencies

Harisch G.,
Dittmann J.

BM, 1999, 1; 4-8.

Different effects on enzymatic activity

In vitro study;
basic research

Contribution to study of the efficacy of homeopathic potencies of phosphorus

Gomez J.C.

BT, 1999, 2; 53-57.

Effect of different potencies of phosphorus

Tests on guinea pigs

Determination of the activity of acid phosphatase in the presence of Ubichinon comp.

Harisch G.,
Dittmann J.

BM, 1999, 4; 188-194.

Effect of enzymatic activity of homeopathic medicine

Basic research

Biochemical efficacy of homeopathic and electronic preparations of D8 potassiumcyanate

Dittmann J.,
     Kanapin H.,
Harisch G.

FKM, 1999, 6; 15-18.

Homeopathic potentisation is more effective than electronic potentisation

Basic research

Osteoporosis in vitro in rat tibia derived osteoblasts is promoted by the homeopathic preparation, FMS Calciumfluor

Palermo C.,
     Filanti C.,
Poggi S.,
Manduca P.

Cell Biol Int, 1999,<o:p> </o:p>

23(1): 31-40.

Stimulant

Osteogenesis
     (trial with
compound drug)

Thin-layer chromatography (TLC) of homeopathic active constituents

Schmolz M.

BM, 1999, 5;<o:p> </o:p>

248-250.

Constituents of Arnica comp.- Heel® ointment: electrophoresis accelerates their skin penetration.

Basic research

Effect of homeopathic constituents on enzymatic activity.

Basic research

Efficacy of a potentised homeopathic drug in reducing cytotoxic effects produced by arsenic trioxide in mice

Datta S.,
     Mallick P.,
Khuda Bukhsh A.R.

Complement Ther
Med
, 1999Jan;
7 (8): 62-75
(a).

Protective

Arsenic trioxide
toxicity

Efficacy of a potentised homeopathic drug in reducing cytotoxic effects produced by arsenic trioxide in mice

Datta S.,
     Mallick P.,
Khuda Bukhsh A.R.

Complement Ther
Med
, 1999 Sep;
7 (3): 156-63
(b).

Protective

Arsenic trioxide
toxicity

Non-cytotoxic antiviral action of a homeopathic drug

Heine H.

Ärzteitschrift fürNeturheilverfahre, 2000; 41: 542-7.

Stimulant

ã interferon<o:p> </o:p>

synthesis

Efficacy of a potentised homeopathic drug in reducing cytotoxic effects produced by arsenic trioxide in mice

Kundu S.N.,
     Mitra K.,
Khuda Bukhsh A.R.

Complement Ther
Med
, 2000 Sep;
1 (3): 157-65.

Protective

Arsenic trioxide
toxicity

Stimulatory effect of some plant extracts used in homeopathy on the phagocytosis induced chemiluminescence of polymorphonuclear leukocytes

Crocnan D.,
     Greabu M.,
Olinescu R.

Rocz Akad Med
Biochemist
, 2000;
45: 246-254.

Stimulant

Phagocytosis

Difference between the efficacy of single potencies and chords

Dittmann J.,
Harisch G.

BM, 2000, 1; 18-23.

Potency chords are more effective than single potencies

Basic research

Influence of some homeopathic drugs on the catalytic activity of uricase, acid phosphatase and the cytosol glutathion-S-transferase

Dittmann J.,
Kanapin H.,
Harisch G.

BM, 2000, 3;<o:p> </o:p>

125-131

Effect of D8 potencies on three different enzymatic systems

Basic research

Influence of some homeopathic drugs on the catalytic activity of cAMP-dependent protein kinases

Dittmann J.,
     Kanapin H.,
Harisch G.

BM, 2000, 6;<o:p> </o:p>

289-296.

Effect of different potencies of 5 substances on enzymatic activity

Basic research

Neuroprotection from glutamate toxicity with ultra-low dose glutamate

Jonas W.,
     Lin Y.,
Zortella F.

Neuroreport,
2001 Feb 92; 12
(2): 335-9.

Protective

Glutamate toxicity

 KEY: BT = Biomedical Therapy

BM = Biologische Medizin

FKM = Forschung Komplementär Medizin

wikified version of the table

I did it to show how it should be coded, instead of fusing html tags. It lacks font tags and cell size tags.

ORIGINAL/TRANSLATED TITLE AUTHOR(S) PUBLICATION ACTIVITY STUDY
Inhibition of lymphoblast transformation test (LTT) in phytohaemagglutinin Phytolacca americana in homeopathic dilution Colas H,
Aubin M.,
Picard P.,Lebecq J.C.
Ann. Homéopat. 1975 6: 1-11. Inhibitory Lymphoblast transformation